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Chapter I
Introduction
1. INTRODUCTION
1. HIV AND AIDS33
In June 2006, a cumulative total of approximately 80 000 cases of HIV
infection had been reported in the UK and 21 000 of these individuals had acquired
immunodeficiency syndrome (AIDS), of whom 80% had died. Approximately 7500
new cases of HIV were reported in the UK in 2005. The most recent World Health
Organization (WHO) report estimated that 38.6 million adults and 2.3 million
children world-wide were living with HIV at the end of 2005. Globally, heterosexual
transmission accounts for 85% of HIV infections. During 2005, an estimated 4.1
million became newly infected with HIV and an estimated 3 million people died
from AIDS. World-wide, the HIV incidence rate is believed to have peaked in the
late 1990s and to have stabilized subsequently, notwithstanding an increasing
incidence in South-East Asia and China.
Fig. No. 1: Sites of action of anti-HIV drugs.
Fig. No. 2: HIV structure consisting of membrane glycoprotein gp120 and
peptide protein p41 plus an outer membrane of p18 and a nuclear membrane of
p24 protein containing viral RNA and the HIV-1 reverse transcriptase and
integrase.
Above inoculation of a naive host with biological fluid (e.g. blood, blood
products or sexual secretions) containing HIV-1, the virus adheres to cells, e.g.
lymphocytes, macrophages and dendritic cells in the blood, lymphoid organs or
central nervous system, expressing the CD4 receptor and chemokine coreceptors
(e.g the CXC chemokine receptor 4 (CXCR4) and the chemokine receptor 5
(CCR5)). During entry, gp120 attaches to the cell membrane by binding to the CD4
receptor. Subsequent interactions between virus and chemokine co-receptors (e.g.
CXCR4 and CCR5) trigger irreversible conformational changes. The fusion event
takes place within minutes by pore formation and releases the viral core into the cell
cytoplasm. The virus then disassembles and the viral reverse transcriptase produces
complementary DNA (cDNA) coded by viral RNA. This viral DNA is then
integrated into the host genome by the HIV-1 integrase enzyme. Viral cDNA is then
transcribed by the host, producing messenger RNA (mRNA) which is translated into
viral peptides. These peptides are then cleaved by HIV protease to form the
structural viral proteins that, together with viral RNA, assemble to form new
infectious HIV virions. These exit the cell by endosomal budding. Figure 8.
illustrates the HIV-1 life cycle, together with current and potential therapeutic
targets. Newly formed HIV-1 virions infect previously uninfected CD4/CCR5-
positive cells and subsequently impair the host immune response by killing or
inhibiting CD4/CCR5-positive cells, thus rendering the host immunosuppressed and
consequently at high risk of infections by commensal and opportunistic organisms.
The diagnosis of HIV-1 infection is based on a combination of the enzyme-linked
immunosorbent assay (ELISA) techniques that identify HIV-1 antibodies and
Western blotting is then used to confirm the presence of HIV-1 structural nproteins
in blood (see Figure No. 2). Massive viral replication n(3 _ 109 virions per day)
occurs in the four to eight weeks immediately post HIV-1 infection. Viral replication
falls in 8–12 weeks, and stabilizes within 6–12 months, initiating a latentmnperiod
of good health which may last 5–12 years. During this latent period, the viral load
falls from an initial peak and remains stable at a plateau of 102–106 HIV RNA copy
number/mL of plasma. The HIV RNA copy number then rises before the
development of AIDS. During the latent phase, there is a dynamic equilibrium of
HIV replication, T-cell infection and destruction and new T-cell generation with a
slow and inexorable decline in CD4_ cell numbers. Only after theCD4 lymphocyte
cell count has fallen to 200–500/_L is the individual predisposed to opportunistic
infections (e.g. pneumocystis, tuberculosis) or malignancies (e.g. Kaposi’s sarcoma,
lymphoma). It is these infections and malignancies that define the later stages of
HIV-1 infection, known as AIDS.
GENERAL PRINCIPLES FOR TREATINGGENERAL PRINCIPLES FOR
TREATING HIV-SEROPOSITIVE INDIVIDUALS:
The accepted standard for HIV treatment is that combination highly active
antiretroviral therapy (HAART) should be administered before substantial
immunodeficiency intervenes. The primary aim of treating patients with HIV
infection is maximal suppression of HIV replication for as long as possible. This
improves survival. HAART comprises two nucleoside analogues plus either a
boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor and
reduces viral load to 500 copies of HIV RNA/mL in 80% of patients after 12 months
treatment. Not all patients tolerate triple therapy due to toxicity, and alternate double
therapy may be used. Current British HIV Association (BHIVA) recommendations
for initiating anti-HIV therapy are as follows. All HIV seropositive patients with
symptoms (or AIDS-defining disease) should receive HAART. If the CD4 count is
350 cells per _L or if there is a rapid decline in CD4 count of _300 cells per _L over
12 months, such patients should be treated. Treatment may be deferred and the
patient monitored if asymptomatic and CD4 counts are stable in the range 350–500
cells per _L. The recommended regimens for initial therapy are shown and are
expected to reduce the HIV RNA copy number per mL of plasma by _0.5 log by
week 8 of therapy, and ultimately to undetectable levels, and to maintain this state.
The plasma HIV RNA copy number is the accepted gold standard for monitoring
therapy and is inversely correlated with CD4 count and survival. HIV therapy
guidelines are evolving rapidly, requiringspecialist care. Current principles
emphasize combination therapy, regime convenience, tolerability and lifelong
therapy. Anti- HIV therapy is a complex therapeutic arena, necessitating specialist
supervision.
NUCLEOSIDE ANALOGUE REVERSE TRANSCRIPTASE INHIBITORS
(NRTIs):
Of these agents, only zidovudine (ZDV) has been proved to reduce mortality
in late-stage AIDS. It reduces the incidence of opportunistic infections and possibly
also the rate of progression of HIV-1 infection to AIDS. Other members of the class
include lamivudine (3-TC), stavudine (d4T), didanosine (ddI), emtricitabine (FTC)
and abacavir (ABC). These drugs are used in combinations and are available as
combined products, e.g. 3-TC/ZDV, ABC/3-TC, ZDV/tenofovir. They reduce HIV-
1 viral replication as indicated by plasma HIV RNA load.
ZIDOVUDINE (AZIDOTHYMIDINE)
This was originally synthesized in 1964 in the hope that it would be useful in
treating malignancies. These hopes were not fulfilled, but it was the first nucleoside
analogue effective in treating HIV-1 infection.
Mechanism of action
The parent drug, ZDV, enters virally infected cells by diffusion and
undergoes phosphorylation first to its monophosphate (ZDV-MP) then to the
diphosphate (ZDV-DP), the rate-limiting step, and finally to the triphosphate (ZDV-
TP). The intracellular t1/2 of ZDV-TP is two to three hours. ZDV-TP is a
competitive inhibitor of the HIV-1 reverse transcriptase and when incorporated into
nascent viral DNA causes chain termination. Human cells lack reverse transcriptase
and human nuclear DNA polymerases are much less sensitive (by at least 100-fold)
to inhibition by ZDV-TP, thus producing a selective effect on viral replication. This
mechanism of action is common to all anti-HIV nucleoside analogues.
Adverse effects:
These include the following:
• Dose-dependent bone marrow suppression causing anaemia with
reticulocytopenia and granulocytopenia. This occurred in 15% of patients in the
original studies with high-dose ZDV. At currently recommended doses, it occurs
in only 1–2% of patients;
• Nausea and vomiting;
• Fatigue and headache;
• Melanonychia (blue-grey nail discoloration);
• Lipodystrophy;
• Mitochondrial myopathy (uncommon);
• Hepatic steatosis with lactic acidosis (rarely);
• It is mutagenic and carcinogenic in animals. However, ZDV is used in HIV-
positive pregnant women as it reduces HIV maternal–fetal transmission and thus
fetal/neonatal HIV-1 infection and has not been shown to be teratogenic if given
to women after the first trimester.
Pharmacokinetics:
Zidovudine is almost totally absorbed (_90%) from the gastro-intestinal tract,
it achieves cerebrospinal fluid (CSF) concentrations that are 50% of those in plasma.
The ZDV plasma elimination t1/2 is one to two hours. About 25–40% of a dose
undergoes presystemic metabolism in the liver. The major metabolite (80%) is the
glucuronide and approximately 20% of a dose appears unchanged in the urine.
Lamivudine (3TC)34
It is a reverse transcriptase inhibitor with a relatively long intracellular half-
life (14 h; plasma t1/2 6 h). In combination with zidovudine, lamivudine appears to
reduce viral load effectively and to be well tolerated, although bone marrow
suppression may be produced. Rarely, pancreatitis may occur. Lamivudine has also
been used for treatment of chronic hepatitis B infection, but resistant strains of virus
have been reported.
NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR:
Tenofovir is the first nucleotide (as distinct from nucleoside) reverse
transcriptase inhibitor (NERTI) and is used in combination with NRTIs. It is a
derivative of adenosine monophosphate, but lacks the ribose ring. It is
phosphorylated sequentially to the diphosphate and then the triphosphate which is a
competitive inhibitor of HIV reverse transcriptase. It is adequately absorbed orally
and administered once a day (half life 14–17 hours). It is renally eliminated.
Tenofovir is well tolerated with few adverse effects (mainly flatulence). Occasional
cases of renal failure and Fanconi syndrome have been reported, so it should be used
with caution in patients with pre-existing renal dysfunction. Although it is not a
CYP450 inhibitor or inducer, it increases the AUC of didanosine and reduces the
AUC of atazanavir. Ritonavir and atazanavir increase the AUC of tenofovir.
Tenofovir is also active against hepatitis B virus (HBV).
NON-NUCLEOSIDE ANALOGUE REVERSE TRANSCRIPTASE
INHIBITORS:
The non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs) are
used as part of triple-therapy schedules in combination with nucleoside analogue RT
inhibitors (e.g. ZDV/ 3-TC). Agents in this group include efavirenz, nevirapine and
delavirdine. Efavirenz is administered orally and causes a marked (_50%) reduction
in viral load during eight weeks of therapy. They are synergistic with NRTIs.
NNRTIs should only be used in combination therapy due to the rapid development
of viral resistance.
Mechanism of action:
Non-nucleoside agents inhibit HIV reverse transcriptase by binding to an
allosteric site and causing non-competitive enzyme inhibition, reducing viral DNA
production.
Adverse effects:
These include the following:
• Abdominal pain and nausea/vomiting/diarrhoea;
• Lipodystrophy;
• Arthralgia, myalgia;
• Drug–drug interactions: complex effects on other CYP450 metabolized drugs\
(see below);
• Neural tube defects in the fetus.
Pharmacokinetics:
Efavirenz is well absorbed. It has a plasma t1/2 of 40–60 hours, is highly
protein bound and metabolized by hepatic CYP2B6 _ CYP3A) to its hydroxylated
metabolite, which is glucuronidated and excreted in the urine.
Drug interactions:
Efavirenz inhibits CYP3A4, CYP2C9 and CYP2C19 and may reduce the
clearance of co-administered drugs metabolized by these isoenzyme systems.
Efavirenz autoinduces its own metabolism. In contrast, nevirapine induces CYP3A
and thus increases the clearance of drugs metabolized by this isoenzyme.
HIV PROTEASE INHIBITORS:
Compounds in this class include amprenavir, ritonavir, indinavir, lopinavir,
nelfinavir, saquinavir, atazanavir and tipranavir . They cause a rapid and marked
reduction of HIV-1 replication as measured by a fall of 100- to 1000- fold over 4–12
weeks in the number of HIV RNA copies per mL of plasma. Reductions in viral load
are paralleled by increases in CD4 count of approximately 100–150 cells/μL.
Resistance is a problem and leads to cross-resistance between protease inhibitors
(PIs), so they are used in combination therapy.
Mechanism of action:
These agents prevent HIV protease from cleaving the gag and gag–pol
protein precursors encoded by the HIV genome, arresting maturation and blocking
the infectivity of nascent virions. The HIV protease enzyme is a dimer and has
aspartylprotease activity. Anti-HIV protease drugs contain a synthetic analogue
structure of the phenylalanine–proline sequence of positions 167–168 of the gag–pol
polyprotein. Thus they act as competitive inhibitors of the viral protease and inhibit
maturation of viral particles to form an infectious virion.
Adverse effects:
These include the following:
 Nausea, vomiting and abdominal pain;
 Fatigue;
 Glucose intolerance (insulin resistance or frank diabetes mellitus) and
hypertriglyceridaemia;
 Fat redistribution – buffalo hump, increased abdominal girth;
 Drug–drug interactions – complex effects on many other drugs that are
hepatically metabolized.
Pharmacokinetics:
Lopinavir is well absorbed with food and 98–99% protein bound (albumin
and alpha-1-acid glycoprotein). It undergoes oxidative metabolism by the CYP3A
isozyme, with a half-life of five to six hours. The majority of lopinavir is excreted as
metabolites in the faeces, with only about 4% appearing in urine. Ritonavir is also
well absorbed (bioavailability _60%). It is 60% plasma protein bound and
metabolized by CYP3A _ CYP2D6. It has a half life of between three and five
hours. Ritonavir inhibits the metabolism of certain CYP3A substrates (and certain
drugs metabolized by CYP2D6) and induces its own metabolism. Therefore drug–
drug interactions are complex.
Drug interactions:
These are numerous and clinically important; the following list is not
comprehensive:
1. Most protease inhibitors are inhibitors of hepatic CYP3A. This leads to
reduced clearance and increased toxicity of a number of drugs often causing
severe adverse effects (e.g. increased sedation with midazolam, triazolam and
excessive hypotension with calcium channel blockers). Protease inhibitors
inhibit the metabolism of rifabutin increasing the risk of rifabutin toxicity.
2. Enzyme inducers (e.g. rifamycins – rifampicin/rifabutin or nevirapine) enhance
the metabolism of protease inhibitors, making them less effective, producing
subtherapeutic plasma concentrations and increasing the likelihood of HIV
resistance.
3. Several protease inhibitors reduce gastro-intestinal metabolism (by CYP3A)
and luminal transport (via P-gp/MDR1) of co-administered protease inhibitors,
thereby increasing plasma concentrations. Combining two agents from this
group is called ‘boosted protease inhibitor’ therapy, e.g. lopinavir is available
combined with low-dose ritonavir; ritonavir inhibits CYP3A and P-
glycoprotein (MDR1) increasing the bioavailability of lopinavir. The same
principle applies if saquinavir/ low-dose ritonavir or amprenavir/low-dose
ritonavir are combined.
FUSION INHIBITORS:
Currently, enfuvirtide is the only available HIV fusion inhibitor. This agent
is reserved for HIV patients who have evidence of progressive HIV replication
despite HAART therapy. It is a 36 amino acid peptide analogue of part of the
transmembrane region of gp41 that is involved in the fusion of the virus particle
with the host cell membranes. It is given subcutaneously on a twice daily basis.
Mechanism of action:
The peptide enfuvirtide blocks the interaction between the HIV gp41 protein
and the host cell membrane by binding to a hydrophobic groove in the N36 region of
gp41. Due to this unique mechanism of action, enfuvirtide is active against HIV
which has developed resistance to HAART. Resistance to enfuvirtide can arise by
mutations in its gp41 binding site.
Adverse effects:
These include:
• Injection site reactions – pain, erythema, induration (98% of patients) and
nodules; approximately 5% of patients discontinue therapy because of these
local skin reactions;
• lymphadenopathy;
• flu-like syndrome;
• eosinophilia;
• biochemical hepatitis.
Pharmacokinetics:
Enfuvirtide is well absorbed after subcutaneous administration and is
distributed in the plasma volume, with 98% bound to albumin. The plasma t1/2 is
three to four hours. The major route of clearance is unknown.
Drug interactions:
Enfuvirtide is not known to cause drug–drug interactions with other anti-HIV
drugs.
CHANGING ANTI-HIV THERAPY FOR TREATMENT FAILURE AND/OR
RESISTANCE:
A change in anti-HIV therapy may be required because of treatment failure,
adverse effects, poor compliance, potential drug–drug interactions or current use of a
suboptimal regimen. Viral resistance to NRTIs and NNRTIs and protease inhibitors
may cause treatment failure. Reduced susceptibility of HIV-1 isolates to
NRTIs/NNRTIs and PIs is developing. Genetic testing of the HIV genome for
mutations leading to drug resistance in isolates from individual patients is becoming
more widely available and may guide therapy. Resistance to ZDV emerges more
quickly and to a greater degree in the later stages of the disease. Progressive
stepwise reductions in susceptibility of the HIV reverse transcripase (RT) correlate
with the acquisition of mutations in the gene for the RT protein. In the case of ZDV,
the only cross-resistance is to other nucleosides with the 3_-azido side-chain and
therefore such isolates are still sensitive to 3-TC, d4T/ddI. Future prospects include
more potent protease inhibitors, novel entry inhibitors e.g. maraviroc, HIV-integrase
inhibitors e.g. raltegravir and effective anti-HIV vaccines.
2.Controlled release Dosage Form:
This is reflected by the fact that well over 80% of the drugs in United States
that are formulated to produce systemic effects are marked as oral dosage forms
Compared with other oral dosage forms, tablets is  manufacturer’s  choice because
of their
 Relatively low cost of Manufacturing
 Packaging
 Shipping
 Increased stability and virtual tamper resistance.
2.1 TABLETS1
Tablets are solid preparations each containing a single dose of one or more
active substances and usually obtained by compressing uniform volumes of
particles. The particles consist of one or more active substances with or without
excipients such as diluents, binders, disintegrating agents, glidants, lubricants,
substances capable of modifying the behaviour of the preparation in the digestive
tract, colouring matter authorised by the competent authority and flavouring
substances.
ADVANTAGES OF TABLET2,3,4
Some of the potential advantages of tablets are as follows .They are the
unit dosage forms having greatest capabilities amongst all the oral dosage form for
the dose precision and least content variability.
 Low cost amongst all the oral dosage forms.
 They are the lightest and the most compact amongst all the oral dosage form.
 Product identification requires no additional processing steps when
employing an embossed or monogrammed punch face.
 Provides greatest ease of swallowing with the least tendency for hang up
above the stomach.
 They are easiest and cheapest for packaging and transportation.
 They lend themselves to certain special release profile products such as
enteric or delayed release products.
 Tablets are better suited to large-scale production than other unit oral dosage
forms.
 They have the best-combined properties of chemical, mechanical,
microbiological stability amongst all the oral dosage forms.
 Emergencies supplies of the drug can be conveniently carried by the patient.
TYPES OF TABLETS
Tablets are divided into classes based on their route of administration and their
function.
I. Tablets administered orally
i. Compressed tablets
 Sugar coated tablets
 Film-coated tablets
 Enteric-coated tablets
 Chewable tablets
 Controlled release tablets
ii. Multiple compressed  tablets
 Layered tablets
 Press coated tablets
II. Tablets administration in oral cavity
i. Buccal and sublingual tablets
ii. Lozenges and troches
iii. Dental cores
III. Tablet administered via other routes
i. Implants
ii. Compressed suppositories or Inserts
IV. Tablets administered in solution form
i. Effervescent tablets
ii. Dispensing tablets
iii. Hypodermic tablets
iv. Tablets triturates
2.2 AN INTRODUCTION TO CONTROLLED RELEASE DOSAGE FORMS6&8:
The R&D laboratories have brought the concept, “Development &
optimization of rate controlled drug delivery” The science and technology of rate
controlled administration of the drug substance has generated wide application for
future to come. Many categories of drug substances have been exploited as a
candidate for such type of drug delivery systems.
Curing of the patient suffering from any kind of pain and inflammation is
also favourable through such type of drug delivery system. The oral route of
administration has been used for both conventional and novel drug delivery systems.
There are many obvious reasons for the same, not the least of which would include
acceptance by the patient and ease of administration. The types of sustained and
controlled-release systems employed for oral administration include virtually every
currently known theoretical mechanism for such application. This is because there is
more flexibility in dosage design, since constraints, such as sterility and potential
damage at the site of administration are minimized. Because of this, it is convenient
to discuss the different types of dosage forms by using those developed for oral
administration as initial examples.
Most orally administered drug, targeting is not a primary concern, and it is
usually intended for drugs to permeate to the general circulation and perfuse to other
body tissues for this reason, sustained-release system are employed. It is assumed
that increase circulating blood levels which, in turn, promotes greater concentrations
of drug at the site of action. If toxicity is not as issue, therapeutic levels can thus be
extended. In essence, drug delivery by these systems usually depends on release
from some type of dosage form, permeation though the biological milieu and
absorption through an epithelial membrane to the blood. There are a variety of both
physicochemical and biological factors that plays important roll in the design of
such systems.
To maintain the drug concentration within therapeutic range, it is necessary
to take these conventional dosage forms frequently. This may lead to the peak and
valley type of drug concentration in the body. It is explained in the following
graphical presentation.
Fig. No.3- A hypothetical plasma concentration-time profile from
conventional multiple dosing and single doses of sustained and controlled
delivery formulations.
The goal of any drug delivery system is thus to provide a therapeutic
amount of drug to the proper site in the body, secondly to achieve promptly and then
maintain the desired drug concentration for therapeutic benefits. The idealized
objective points to the two aspects most important to the drug delivery namely,
spatial placement and temporal delivery of drug. Spatial placement relates to the
targeting of a drug to specific organ or tissue while temporal delivery refers to
controlling the rate of drug delivery to target tissue. An appropriately designed
controlled release delivery system can be a major advance towards solving these two
problems.
There are many definitions of controlled release but the simplest definition is
“Any drug or dosage form or medication that prolongs the therapeutic activity of
drug’’. The overall objective is that, once the drug-carrier material has been injected
or otherwise implanted or taken orally into the body, the drug is released at a
predetermined rate for some desired period of time. Controlled release technology is
relatively new field and as a consequence, research in this field has been extremely
fertile and has produced many discoveries.
Several terms have been used to describe the various types and modes of
action intended to provide long duration of drug activity. Unfortunately, the terms
have been applied loosely and are interchanged invariably so that today there is no
consistent nomenclature for the prolonged action products available in the market.
Several nomenclatures have been utilized synonymously to describe controlled
release medications. Some of these are: continuous release (CR), depot release (DR),
slow release (SR), long acting (LA), long lasting (LL), long term release (LTR),
prolonged action (PA), controlled release (CR), extended release (ER), gradual
release (GR) etc. The United States Pharmacopoeia (U.S.P.) has adopted the term
extended release whereas British pharmacopoeia (B.P.) has adopted the term slow
release. The Indian pharmacopoeia (I.P.) does not make any reference to controlled
release products. The food and drug administration (F.D.A.) of United States has
adopted the term prolonged release. Various other designations such as smart
release, targeted release, repository release, intelligent release, protracted release,
spaced release have been assigned to describe sustained release systems. However,
the recent literature survey indicates that as on today the most widely used terms are
controlled release and sustained release.
The aim of controlled release delivery of drugs, in a general way is to
modify the normal behavior of drug molecule in physiological environment. It can
lead to the following: -
1. Controlling drug action at a predetermined rate by maintaining a relatively
constant effective drug level in the body with concomitant minimization of
undesirable side effects.
2. Localization of drug activity by spatial placement of a control release system
adjacent to or within the diseased tissue or organ.
3. Targeting drug action by using specific carriers or chemical derivatives to
deliver drugs to particular target cell type
ADVANTAGES OF CONTROLLED RELEASE SYSTEM 4&7.
Therapeutic efficacy and safety of controlled release dosage formulations
attained as a result of providing a nearly constant pharmacological response, there
by avoiding the normal peack and valley pattern associated with multiple dosing of
conventional drug product.
 Control drug release improves patient convenience.
 Decrease incidences of adverse drug reactions.
 Increased safety margin of high potency drug dye to better control of plasma
levels.
 Maximum utilization of drug enabling reduction total amount of dose
administered.
 Controlled release dosage form will provide therapeutic concentration of the
drug in the blood that is maintained throughout the dosing interval.
 Reduction in health care costs through improved therapy, shorter treatment
period less frequency of dosing and reduction in personnel time to dispense
administer and monitor patients.
2.3 PHYSIOCHEMICAL PROPERTIES OF THE DRUG SUBSTANCE
SUITABLE FOR ORAL CONTROLLED RELEASE DOSAGE FORMS8&32
Some characteristics make a drug more suitable for controlled release
dosing, such as-
1. Elimination half-life between 2 to 8 hours.
2. Broader therapeutic index.
3. Moderate unit dose
4. Significant extent of absorption in GIT.
5. Optimum solubility characteristics.
6. Minimal first-pass clearance.
2.4 FACTORS INFLUENCING THE PERFORMANCE OF ORAL
CONTROLLED RELEASE PRODUCTS8&32:
Oral drug delivery is the most widely utilized route of administration
among all the routes that have been explored for the systemic delivery of drugs via
various pharmaceutical products in different dosage forms. Irrespective of their
mode of delivery (immediate, sustained or controlled release) and the design of
dosage forms (either solid or liquid) they must be developed within the intrinsic
characteristics of GI physiology. Therefore a fundamental understanding of
pharmacokinetics, pharmacodynamics and formulation design is essential to achieve
a systematic approach to the successful development of an oral pharmaceutical
dosage form.
A number of variables such as drug properties, route of delivery, target sites,
duration of therapy, the disease state and patient variables must be considered. The
formulation and performance of sustained release products are greatly influenced by
the physicochemical and biological properties of drug.
2.5 PHYSICOCHEMICAL PROPERTIES OF A DRUG AFFECTING DRUG
PRODUCT DESIGN AND PERFORMANCE6,8&32.
1. DOSE SIZE:
Single oral dose greater than 200mg are poor candidates for the oral
controlled release products as the maintainence dose will be unacceptably large
depending on the density of the drug, duration of intended prolongation and type of
controlling mechanism.
2. AQUEOUS SOLUBILITY:
Since drugs must be in solution before they can be absorbed, compounds
with very low aqueous solubility usually suffer oral bioavailability problems
because of limited gastrointestinal transit time of the undissolved drug particles and
limited solubility at absorption site e.g. warfarin and griseofulvi Hence diffusion
controlled systems will be poor choice for such drugs.
Drugs having very high aqueous solubility and drugs exhibiting pH-
dependent solubility may also pose problems for their incorporation in oral
controlled release system.
3. DRUG STABILITY:
Since most of the controlled release preparations are designed to release the
drug over the entire length of GI tract, drugs that are unstable in gastric or intestinal
environment are unsuitable for sustained release dosage form.
4. pKa:
The uncharged form of a drug is preferentially absorbed through many body
tissues. The release of an ionisable drug from a controlled release unit should hence
be programmed in accordance with variation in pH of the gastro-intestinal tract so
that the amount of preferentially absorbed uncharged species and the plasma levels
of the drug will be approximately constant throughout the duration of action.
2.6 CLASSIFICATION OF POLYMERIC DRUG CONTROLLED RELEASE
DRUG DELIVERY SYSTEMS32:
Once a drug candidate is thoroughly investigated and found suitable, it is
needed to select, the controlled release technology that best fits the intended
application and the basic physical form of device and the rate-controlling polymer
matrix to be used.
The various controlled release polymeric systems can be classified depending
upon the mechanism of controlling the drug release, as follows:
I. Chemically controlled systems
i) Biodegradable systems
ii) Drug –polymer conjugates
II. Diffusion-controlled systems
i) Membrane-reservoir systems
ii) Matrix systems
I. CHEMEMICALLY-CONTROLLED SYSTEMS:
i) BIODEGRADABLE SYSTEMS:
In this system, the matrix-forming polymer contains hydrolytically or
enzymatically labile bonds and drug is uniformly dissolved or dispersed in this
matrix. As the polymer erodes by hydrolysis or enzymatic cleavage, the drug is
released to the surrounding environment. The erosion process has a direct effect on
drug release.
ii) DRUG-POLYMER CONJUGATES:
This system involves drug molecules chemically bonded to a polymer
backbone. The drug will be released through hydrolytic or enzymatic cleavage of
these bonds. The attachment of drugs to macromolecular carriers alters their rate of
excretion from the body and provides the possibility for sustaining the release over a
prolonged period.
II. DIFFUSION-CONTROLLED SYSTEMS 7,21&24:
i) MEMBRANE-RESERVOIR SYSTEM:
The kinetics of drug release from membrane-reservoir systems generally
follows either a solution diffusion mechanism or an osmotic pumping mechanism.
In the solution-diffusion mechanism, the drug transport occurs by first
dissolving in the reservoir membrane at one interface followed by diffusion down a
chemical potential gradient across this membrane and eventually released from the
second interface into the external medium. Such solution-diffusion mechanism is
typically observed in non-porous membranes.
In the osmotic pumping mechanism, a semi permeable membrane is utilized
to regulate the osmotic permeation of water/GI fluid. The rate of osmotic water
influx and therefore the rate of drug delivery will be constant as long as a constant
thermodynamic activity gradient is maintained across the membrane. The delivery
rate from such devices is generally regulated by osmotic pressure of the drug core
formulation and by the water permeability of the semipemeable membrane.
ii) MATRIX SYSTEMS:
Matrix system is one of the least complicated approaches to manufacture the
sustained release dosage forms. Matrix systems can be classified based on the
mechanism of controlling the drug release as follows:
a. Matrix diffusion
b. Polymer erosion
c. Polymer swelling
a. MATRIX DIFFUSION:
Historically, the most popular diffusion-controlled delivery system has been
the matrix system. However, the inherent drawback of the matrix system is its first-
order release behaviour with continuously diminishing release rate. This is a result
of the increasing diffusional resistance and decreasing area at the penetrating
diffusion front.
The kinetics of drug release from homogeneous dispersed-drug matrix
devices (which acts as a diffusional medium) can be given by Higuchi’s equation,
Q = [D t (2A - Cs) Cs] ½
where Q = amount of drug released after time t,
D = diffusivity of the drug in the homogenous matrix media,
Cs = the solubility of the drug in the matrix substanc
A = surface area of drug particle.
b. POLYMER EROSION:
The release of a dissolved drug or dispersed drug from an erodible polymer
matrix can be controlled by a variety of mechanisms ranging from
hydrolysis/enzymatic cleavage to swelling and dissolution. The situation where
polymer erodes by a purely heterogeneous process, viz.surface erosion, is of special
interest because the drug release from such devices having constant geometry will
be at constant rate.
c. POLYMER SWELLING:
Swelling phenomena are generally encountered in both the hydrophilic and
hydrophobic polymer matrices during the release of entrapped water-soluble drug in
an aqueous environment.
Among different  technologies use in controlled drug delivery hydrophilic
matrix system are the most popular because of the simplicity of formulation, ease of
manufacturing  low cost , FDA acceptance and applicability to drug with wide range
of solubility.
2.7 FORMULATION OF ORAL CONTROLLED RELEASE DOSAGE
FORMS:
Oral  polymeric matrices are commonly employed to achieve controlled
release of drugs when a hydrophilic matrix is placed in an aqueous medium  the
hydrophilic colloid component swells to form a gelatinous surface layer this then
controls the diffusion of water into the matrix release of drugs from such a system is
governed by two mechanism (I) diffusion of water-soluble drug through the gel
layer and (ii)  release of a water soluble or water insoluble drug by erosion of the
outer gel layer as it becomes well-hydrated within the hydrated surface layer of the
matrix the core remains drug acting as a non-releasing reservoir of drug polymer.
Extensive research has been carried out in the field of development of oral
controlled release dosage forms, which are mostly in the form of tablets and
capsules. A wide variety of materials has been tried for controlling/sustaining drug
release and these include wax, carnauba wax, stearic acid, stearyl alcohol, synthetic
polymers such as polyvinyl alcohol, polyvinyl chloride, polyvinyl pyrolidone, and
acrylates; hydrocolloids and gums such as methyl cellulose, corboxy methyl
cellulose, hydroxy propyl methyl cellulose, xanthan gum, guar gums, silicones and
related polymers and also ion exchange resins.
The technologies adopted for design of oral extended release dosage forms
are barrier coating, embedment matrix, micro encapsulation, use of ion exchange
resins and Osomotically-controlled devices.
2.8 BIOMATERIALS FOR DELIVERY SYSTEMS15
A range of materials have been employed to control the release of drugs and other
active agents. The earliest of these polymers were originally intended for other,
nonbiological uses, and were selected because of their desirable physical properties,
for example:
Poly(urethanes) for elasticity.
Poly(siloxanes) or silicones for insulating ability.
Poly(methyl methacrylate) for physical strength and transparency.
Poly(vinyl alcohol) for hydrophilicity and strength.
Poly(ethylene) for toughness and lack of swelling.
Poly(vinyl pyrrolidone) for suspension capabilities.
To be successfully used in controlled drug delivery formulations, a
material must be chemically inert and free of leachable impurities. It must also
have an appropriate physical structure, with minimal undesired aging, and be
readily processable. Some of the materials that are currently being used or
studied for controlled drug delivery include
Poly(2-hydroxy ethyl methacrylate).
Poly(N-vinyl pyrrolidone).
Poly(methyl methacrylate).
Poly(vinyl alcohol).
Poly(acrylic acid).
Polyacrylamide.
Poly(ethylene-co-vinyl acetate).
Poly(ethylene glycol).
Poly(methacrylic acid).
However, in recent years additional polymers designed primarily for
medical applications have entered the arena of controlled release. Many of these
materials are designed to degrade within the body, among them
Polylactides (PLA).
Polyglycolides (PGA).
Poly(lactide-co-glycolides) (PLGA).
Polyanhydrides.
Polyorthoesters.
Originally, polylactides and polyglycolides were used as absorbable suture
material, and it was a natural step to work with these polymers in controlled drug
delivery systems. The greatest advantage of these degradable polymers is that they
are broken down into biologically acceptable molecules that are metabolized and
removed from the body via normal metabolic pathways. However, biodegradable
materials do produce degradation by-products that must be tolerated with little or no
adverse reactions within the biological environment.
These degradation products—both desirable and potentially nondesirable—
must be tested thoroughly, since there are a number of factors that will affect the
biodegradation of the original materials. The most important of these factors are
shown in the box below—a list that is by no means complete, but does provide an
indication of the breadth of structural, chemical, and processing properties that can
affect biodegradable drug delivery systems.
FACTORS AFFECTING BIODEGRADATION OF POLYMERS18
 Chemical structure.
 Chemical composition.
 Distribution of repeat units in multimers.
 Presents of ionic groups.
 Presence of unexpected units or chain defects.
 Configuration structure.
 Molecular weight.
 Molecular-weight distribution.
 Morphology (amorphous/semicrystalline, microstructures, residual stresses).
 Presence of low-molecular-weight compounds.
 Processing conditions.
 Annealing.
 Sterilization process.
 Storage history.
 Shape.
 Site of implantation.
 Adsorbed and absorbed compounds (water, lipids, ions, etc.).
 Physicochemical factors (ion exchange, ionic strength, pH).
 Physical factors (shape and size changes, variations of diffusion coefficients,
mechanical stresses, stress- and solvent-induced cracking, etc.).
 Mechanism of hydrolysis (enzymes versus water).
2.9 CLASSIFICATION OF POLYMERS USED IN CONTROLLED
RELEASE DRUG DELIVERY SYSTEMS18&20:
Polymers are complex and giant molecules known as macromolecules
consisting of many repeating units and are formed by process called as
polymerization.
In general polymers can be classified in to three distinct categories i.e.
natural, synthetic and semi synthetic
Natural polymers include nucleic acids, polysaccharides, complexes of
proteins and polysaccharides. Synthetic polymers belong to classes of polyesters,
polyurethanes, polyamides, polycarbonates, polyolefins, polyvinyls, acrylics etc.
Pharmaceutical formulators have employed natural polymers for hundreds of
years and more recently the chemical modifications of some of these have provided
a range of materials with improved performance. The choice regarding polymers
used as release retardants for drug delivery systems depends upon their availability,
cost, mechanical and physical properties and regulatory acceptance. The polymers
used in extended release dosage forms can be classified as
2.9.1 CLASSIFICATION OF POLYMERS USED IN SUSTAINED RELEASE
DRUG DELIVERY SYSTEMS ACCORDING TO THEIR
CHARACTERISTICS20:
Polymers can also be classified on the basis of their interaction with water
into:
(a) Non-biodegradable hydrophobic polymers
(b) Hydrogels
(c) Soluble polymers
(d) Biodegradable polymers
2.9.2 CHARACTERISTICS OF IDEAL POLYMER SYSTEM
 It should be chemically inert and free from leachable impurities.
 It should have good mechanical strength.
 It should be non-toxic and compatible with the environment.
 It should be easy and inexpensive to fabricate.
 It should be easily sterilized.
 It should demonstrate acceptable shelf life.
In addition to carrier systems containing single polymeric systems,
researchers are working on carrier systems containing block copolymers. These are
the polymers formed through polymerizatioin of two or more monomers. These
networks when composed of hydrophilic and hydrophobic monomers are called
polymer micelle. These micelles are suitable for enclosing individual drug
molecules. Their hydrophilic outer shells help to protect the cores and their contents
from chemical attack by the aqueous medium. Most micelle based systems are
formed from poly(ethylene oxide)-bpolypropylene-b-poly(ethylene oxide) triblock
network. In one of the studies carried out, micelles were used as a hydrophobic
(doxorubicin) anticancer agent. The results revealed that when dose of drug
intravenously was given, the system could withstand the body’s normal blood
circulation and effectively deliver the medication to a solid cancerous tumor.
2.9.3 DRUG RELEASE MECHANISMS FOR POLYMERIC DRUG
DELIVERY8&32
Two broad categories of polymer systems have been studied. The reservoir
device involves the encapsulation of a drug within a polymer shell, while the matrix
device describes a system in which a drug is physically entrapped within a polymer
network.
Fig.No.4:- Possible drug release mechanisms for polymeric drug delivery.
As shown in Fig.No.2 the drug will be released over time either by diffusion
out of the polymer matrix or by erosion (due to degradation) of the polymer or by a
combination of two mechanisms. Reviews have been presented on the mechanisms
and the mathematical aspects of release of   drug from polymer matrices.
Drug Release
Diffusion Polymer Degradation Combination
Enzymatic
Degradation
Hydrolysis Combination
Bulk erosion Surface erosion
Fig.No.5:- Drug delivery from (a) bulk eroding and (b) surface eroding
biodegradable system.
Table No.1:- List of polymers and their application20.
POLYMER APPLICATION AND COMMENT
NATURAL POLYMERS
Proteins and protein-based
polymers
Absorbable, biocompatible, nontoxic, naturally
available, typically elastic materials used as
implants and in tissue engineering.
Collagen Absorbable sutures, sponge wound dressing,
drug delivery microspheres.
Albumin Used in cell and drug microencapsulation.
Poly (amino acids) Nontoxic, nonantigenic and biocompatible.
Used as oligomeric drug carriers.
Polysaccharides and derivatives
From vegetable sources
Carboxymethyl cellulose Cell immobilization via a combination of
ionotropic gelation and polyelectrolyte
complex formation (e.g. with chitosan), in
drug-delivery systems and dialysis membranes.
Cellulose sulphate Component of polyelectrolyte complexes for
immunoisolation.
Agarose Largely used as supporting materials in clinical
analysis and as an immobilization matrix.
Alginate (marine sources, algae) Excellent gel-formation properties,
biocompatible, microstructure and viscosity are
dependent on the chemical composition (batch-
to-batch variations). Used as immobilization
matrices for cells and enzymes, controlled
release of bioactive substances, injectable
microcapsules for treating neurodegenerative
and hormone-deficiency diseases.
Carrageenan Excellent thermoreversible properties.
Used for microencapsulation.
From human and animal
sources
Hyaluronic acid Excellent lubricant, potential therapeutic agent.
Heparin and heparin-like Antithrombotic and anticoagulant.
Microbial polysaccharides
Microbial polysaccharides Microbial polysaccharides.
Chitosan and its derivatives
Biocompatible, nontoxic,
excellent gel- and film-forming
ability,
Natural polymer. Widely used in controlled-
delivery systems.
SYNTHETIC POLYMERS
Aliphatic polyesters
Poly (lactic acid), poly (glycolic
acid) and their copolymers
Used in sutures, drug-delivery systems and in
tissue engineering. Biodegradable, often
copolymerized to regulate degradation time.
Poly (hydroxy butyrate),
poly (e-caprolactone) and
copolymers
Biodegradable, used as a matrix for drug-
delivery systems, cell microencapsulation.
Properties can be changed by chemical
modification, copolymerization and blending.
Polyamides (nylons) Sutures, dressing, haemofiltration membranes.
Polyanhydrides Biodegradable, useful in tissue engineering and
for the release of the bioactive molecules.
Poly (ortho esters) Surface-eroding polymers. Application in
sustained drug delivery, ophthalmology.
Poly (cyano acrylates) Biodegradable, depending on the length of the
alkyl chain. Used as surgical adhesives and
glues, potentially used in drug delivery.
Polyphosphazenes Can be tailored with versatile side-chain
functionality. Made into films and hydrogels.
Applications in drug delivery.
Can be tailored with versatile
side-chain functionality. Made
into films and hydrogels.
Applications in drug delivery.
Good elastomeric properties. Can be tailored
by varying the starting materials. Used in
permanently implanted medical devices
(prostheses, vascular grafts), catheters and drug
delivery systems. Initial candidates for the
artificial heart.
Polyethylene (low density) Sutures, catheters, membranes, in surgery.
Poly (vinyl alcohol) Gels and blended membranes are used in drug
delivery and cell immunoisolation.
Poly (ethylene oxide) Highly ‘biocompatible’. Different polymer
derivatives and copolymers have been utilized
in a variety of biomedical applications.
Poly (hydroxyethyl methacrylate) Hydrogels have been used as soft contact
lenses, for drug delivery, as skin coatings and
for immunoisolation membranes.
Poly (methyl methacrylate) This and its copolymers are used as dental
implants and in bonereplacement.
Poly (tetrafluoroethylene)
(Teflon®)
Vascular grafts, clips and sutures, coatings.
Polydimethylsiloxanes A silicone. Implants in plastic surgery,
orthopedics, blood bags and pacemakers.
Environmentally responsive,
synthetic polymers
Poly (ethylene oxide-b-propylene
oxide)
Surfactants with amphiphilic properties; used
in protein delivery, skin treatments.
Poly (vinyl methyl ether) Nontoxic, temperature-sensitive polymer;
excellent shapememory properties.
Poly (N-alkylacrylamides) Temperature-sensitive gels whose lower critical
solution temperature can be adjusted via co-
monomer incorporation.
2.12 TABLET PRODUCTION METHOD2&16.
Tablets are manufactured by wet granulation, dry granulation or direct
compression method.
2.12.1 WET GRANULATION
Wet granulation is the process in which a liquid is added to a powder in a
vessel equipped with any type of agitation that will produce agglomeration or
granules. These granules after drying are compressed to form tablets.
This method has more operational manipulations, and is more time-
consuming than the other methods. The wet granulation method is not suitable for
drugs, which are thermolabile or hydrolysable by the presence of water in the liquid
binder.
ADVANTAGES OF WET GRANULATION
 Traditional method, works well for many drugs because it imparts
compressibility.
 Useful for fluffy powders that don’t flow well or mix well, thus improving
uniformity important for potent (low dose) drugs.
 Wide range of available excipients.
DISADVANTAGES OF WET GRANULATION
Not useful for moisture sensitive or heat sensitive drugs.
 Need to use a binder in the excipients mix.
 Extra steps for drying and labour, material losses susceptible to
 Contamination, time consuming and expensive.
Fig.No.6:- Wet granulation process of tablet.
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Sieving
MixingGlidant lubricant Disintegrating agent
Compression
2.12.2 DRY GRANULATION
In this technique, there is no use of liquids. The process involves the
formation of slugs. Then the slugs are screened or milled to produce granules. The
granules formed are then compressed to form tablets.
ADVANTAGES OF DRY GRANULATION
 Useful for moisture-sensitive drugs.
 Fewer steps and equipment than wet granulation.
 Less loss of materials e.g. transfer steps (mixer-granulators).
 May be less expensive.
 Less time-consuming.
DISADVANTAGES OF DRY GRANULATION
 Lots of force used to compress the dry mixture.
 This energy input can alter crystal form (polymorphism of drugs can
affect their therapeutic effects).
 Makes very hard granules –disintegration/dissolution can be affected (this
can affect the pharmacokinetic of the drug).
 May generate static – poor powder flow, explosion risk with some
mixtures (need special safety equipment, space, money used)
Fig.No.7:- Dry granulation process of tablet manufacture.
2.12.3 DIRECT COMPRESSION16
The term direct compression is used to define the process by which tablets
are compressed directly from powder blends of active ingredient and suitable
excipients, which will flow uniformly in the die cavity & forms a firm compact.
Direct compression methods are very popular because it reduces the number of steps
involved and the materials required.
ADVANTAGES OF DIRECT COMPRESSION METHOD
 This process is more economical, it requires fewer manufacturing steps, less
processing time & thus reduces labour cost & less process validation.
 There is an optimization of tablet disintegration, in which each primary
 drug particle is liberated from the tablet mass & is available for dissolution.
Mixing
DiluentActive ingredient (S)
(binder )
First compression
(By tablet press or roller compactor)
Commminution
Sieving
MixingGlidant lubricant Disintegrating agent
Second Compression
lubricant
 Disintegrating agents like starch are more effective when processed by direct
compression than wet granulation technique.
Fig.No.8:- Direct compression process of tablet manufacture.
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2. REVIEW OF LITERATURE
Punna Rao Ravi35 et al., Formulate the Oral controlled release matrix
tablets of zidovudine were prepared using different proportions and different
viscosity grades of hydroxypropyl methylcellulose. The effect of various
formulation factors like polymer proportion, polymer viscosity and compression
force on the in vitro release of drug were studied.
R.K.Kar36 et al., Formulate oral controlled release matrix tablets of
Zidovudine (AZT) in order to improve efficacy and better patient compliance.
Tablets were prepared by direct compression method using various proportion of
hydrophilic polymer viz; Eudragit RS100 and RL100 along or in combination with
hydrophobic polymer ethyl cellulose. In vitro release studies were performed using
USP type I apparatus (rotary basket type).
Amit.S.Yadav37 et al., Studied design oral controlled release zidovudine
matrix tablets by using hydroxyl propyl methyl cellulose polymer (HPMC) as rate
controlling factor and to evaluate drug release parameters as per various release
kinetic models. The tablets were prepared by wet granulation method. The granules
were evaluated for angle of repose, loose bulk density, tapped bulk density and
compressibility index, shows satisfactory results.
P Narayana Raju38 et al., The matrix tablets were prepared by using Eudragit
L 100, Poly ethylene oxide and Carbopol 971 P. The granules of Zidovudine using
above polymers were prepared by direct mixing, wet granulation with water and wet
granulation with IPA. This study gives an idea about the feasibility of granulation
process for the preparation of the Zidovudine matrix tablets with different polymers.
Nandita G39 et al., The technologies behind oral drug delivery have
emerged from the mainstream pharmaceutical industry and have become influential
forces in their own right, as evidenced by the burgeoning “drug delivery companies”
that are at the forefront of innovation and hold their own niche market.
G.A. Green40 et al., Controlled-release (CR) medications offer many clinical
and convenience advantages for patients as compared to immediate-release (IR)
formulations. Among these are reductions of fluctuations in drug concentration and
adverse side effects, increased compliance and a more convenient dosing regimen.
The drawback however is the lack of dose flexibility. Many solid oral dosage CR
medications are unsuitable for splitting due to the risk of absorption of a large
amount of drug into the blood stream if the drug delivery system is compromised.
P.Venkatesh41 et al., A high-performance liquid chromatographic method
was developed and validated for the determination of two antiretroviral drugs viz.
Zidovudine and Lamivudine in combined pharmaceutical tablets. The different
analytical performance parameters such as linearity, precision, accuracy, specificity,
limit of detection (LOD) and limit of quantification (LOQ) were determined.
Amit.S.Yadav42 et al., Investigate an attempt was made to formulate the oral
controlled release zidovudine matrix tablets by using Guar gum as rate controlling
polymer and to evaluate drug release parameters as per various release kinetic
models. The tablets were prepared by wet granulation method.
Punna Rao Ravi43 et al., Design oral controlled release matrix tablets of
lamivudine using hydroxypropyl methylcellulose (HPMC) as the retardant polymer
and to study the effect of various formulation factors such as polymer proportion,
polymer viscosity, and compression force on the in vitro release of drug.
G.Deepali44 et al., Developed A rapid, simple, accurate, and economical
spectrophotometric method has been developed and validated for the assay of the
anti-retroviral agent lamivudine in active pharmaceutical ingredients (API) and in its
tablet formulation. The analysis is based on the UV absorbance maxima at about
270nm wavelength of lamivudine, using methanol as solvent.
Ravi PR45 et al., Designed oral controlled release (CR) matrix tablets of
zidovudine (AZT) using hydroxypropyl methylcellulose (HPMC), ethyl cellulose
(EC) and carbopol-971P (CP) and to study the effect of various formulation factors
on in vitro drug release. Release rate decreased with increase in polymer proportion
and compression force. The release rate was lesser in formulations prepared using
CP (20%) as compared to HPMC (20%) as compared to EC (20%).
Emeje M46 et al., Designed Oral sustained release matrix tablets of
zidovudine (ZDV) were prepared using different types, proportions and blends of
carbopol 71G (C71) and a plant gum obtained from Abelmoschus esculentus (AEG).
The effect of various formulation factors like polymer proportion, polymer type and
pH of the dissolution medium on the in vitro release of the drug was studied.
Kayitare E47 et al., Designed paediatric antiretroviral formulations on the
market, a novel fixed dose combination (FDC) tablet containing 300mg zidovudine
(AZT) and 150mg lamivudine (3TC) was developed to improve dosing accuracy and
allow flexible drug dosing in function of the body weight of paediatric HIV patients
as recommended by WHO.
Talukdar48 et al., Have done the comparative study on xanthan gum and
HPMC as matrices for controlled release drug delivery. They have concluded that
drug diffusion in hydrated HPMC matrices is higher than in hydrated xanthan gum
matrices. This showed that xanthan gum has higher ability than HPMC to retard the
release of drug when used as matrix forming agent.
Etentakis49 et al., Developed and evaluated the oral multiple unit and single
unit Hydrophilic controlled release systems. Single unit dosage forms i.e. tablet and
capsule and multiple unit dosage form i.e. mini tablets in capsule were prepared.
Tablets and mini tablets showed greater sustained release effect compared with
capsules.
Kranz50 et al., Studied the drug release mechanism from HPMC matrices
and developed a new model for quantitative predictions of controlled drug delivery.
Katikaneni and Neau51 et al., Used ethyl cellulose for formation of matrix
controlled release tablets of a water soluble drug. They have prepared tablets with
direct compression technique. They concluded that ethyl cellulose matrices showed
sustained drug release over a period of 10 h. and the lower viscosity grades of ethyl
cellulose are more compressible than higher viscosity grades resulting in harder
tablets and slower release rates.
Ford and Velasco52 et al., Studied the influence of drug: (HPMC)
(Hydroxymethylpropylcellulose) ratio and other technological factors such as drug
and polymer particle size and compression force on the drug release from the
matrices of HPMC. The influence was assessed by multiway analysis of variance.
They reported that release from HPMC ratio. The particle size also influenced the
release to lesser extent and the compression force didn’t affect the release
parameters.
Divya A53 et al., Bilayer tablet technology, Bilayer tablet is new era for the
successful development of controlled release formulation along with various features
to provide a way of successful drug delivery system.
Sachin S. Kale54 et al., Bilayer tablet is improved beneficial technology to
overcome the shortcoming of the single layered tablet. There is various application
of the bilayer tablet it consist of monolithic partially coated or multi-layered
matrices. In the case of bilayered tablets drug release can be rendered almost
unidirectional if the drug can be incorporated in the upper nonadhesive layer its
delivery occurs into the whole oral cavity.
Krishna Vamshi Allam55 et al., This review briefly discusses about the
novel dosage forms like controlled release matrix tablets, floating tablets,
nanoparticles, microparticles, liposomes, and niosomes; which may possibly suitable
for the controlled and/or sustained release of Lamivudine and thus, useful in
developing the more effective AIDS therapy with very less or no adverse side
effects.
Remeth Jacky Dias56 et al., This study was to design and optimize an oral
controlled release acyclovir mucoadhesive tablet, in term of its drug release and
mucoadhesive strength. A 32 full factorial design was employed to study the effect
of independent variables like Carbopol-934P and Hydroxypropyle methylecellulose
K100, wchich significantly influence charactarastics like swelling index, ex-vivo
mucoadhesive strength and in-vitro drug release.
MA Naeem57 et al., Developed and characterize bilayer tablet formulations
of tramadol HCl (TmH) and acetaminophen (AAP) microparticles.
P.Hiremath58 et al., Studied the design and controlled release matrix tablets
of Rifampicin and Isoniazid using HPMC.
S.B. Tiwari59 et al., Studied the influence of hydrodynamic conditions on
Verapamil hydrochloride release from a hydrophilic matrix using ionic and non-
ionic polymers.
Kiattisalc Saeia60 et al., Studied the factors influencing drug dissolution
characteristic from hydrophilic polymer matrix tablet.
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3. AIM AND OBJECTIVES
AIM OF THE STUDY:
Lamivudine and Zidovudine are belongs to the class of Nucleoside reverse
transcriptase inhibitor which are most widely used in the treatment of HIV infection
either alone or in combination with other antiviral drugs to increase efficacy,
minimize resistance and side effect. The advantage of the development of controlled
release dosage form is reducing the frequent dosing and improves the patient
compliance.
The main aim of this work was to formulate and in vitro evaluate controlled
release bilayer matrix tablet of Lamivudine and Zidovudine by using hydrophilic
polymer HPMC (K 100 and K 15) of different grades and different concentration to
study the drug release pattern.
OBJECTIVE OF THE STUDY:
 To formulate the Oral controlled release bilayer matrix tablet of Lamivudine
and Zidovudine.
 To study the effect of  different grades of polymer (HPMC K 100 and HPMC
K 15) on drug release .
 Evaluation of the post-compression parameters and drug release profile.
 Selection of the best formulation.
 To analyse the mechanism of drug release for best formulation.
 To avoid the side effect of the Drug.
 To improve the patient compliance.
 To improve the antiviral activity.
 To reduce the risk of emergence of resistance to antiretroviral drugs.
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4. DRUG PROFILE
Table No 4.1. Drug Profile of Lamivudine84,85&86:
SR.
NO. PARTICULARS DESCRIPTION
1 Name Lamivudine
2 Category Anti-Retroviral agent
3 Chemical
Formula
C3H11N3O3S
4 Molecular
Weight
229.2560
5 IUPAC Name 4-amino-1-[(2R,5S)-2-(hydroxyl methyle)-1,3-
oxothioline-5-yl] pyramidine-2-one.
6 Chemical
Structure
7 Half Life 5-7 hrs.
8 Dosage Form Tablet, Capsule etc.
9 Solubility
(mg/ml)
70 mg/ml(water)
10 Max. Daily Dose 300 mg/day
11. Melting pt. 160-1620C
12 Protein Binding <36%
13 Bioavailability 80-87%
14 Absorption * After oral administration it is rapidly absorb
through gastrointestinal tract.
15 Distribution * Believed to be distributed into the extravascular
spaces.
* Vd is independent of dose and doesn’t correlate
with body weight less than 36% is bound to plasma
proteins.
16 Metabolism * Metabolism is the minor route of elimination. The
only known metabolite is trans sulfoxide metabolite.
17 Excretion Primarily eliminated unchanged in urine.
18 Mechanism Of
Action
* Lamivudine is a nucleoside reverse transcriptase
inhibitor (NRTI) with active against Human
Immunodeficiency Virus Type-1 (HIV-1) and
Hipatitis b (HBV).
* Lamivudine is phosphorylated to active metabolite
that compete for incorporation into viral DNA.
* They inhibit the HIV reverse transcriptase enzyme
competitively and act as a chain terminator of DNA
synthesis. Thus the viral DNA growth is
Terminated.
19 Indication Lamivudine are a nucleoside analogue indicated in
combination with other antiretroviral agents for the
treatment of human immunodeficiency virus (HIV-
1) infection. Limitation of use: The dosage of this
product is for HIV-1 and not for HBV.
Table No. 4.2. Drug Profile of Zidovudine84,85&87:
Sr.
No.
PARTICULARS DESCRIPTION
1 Name Zidovudine.
2 Category Anti-Retroviral agent
3 Chemical Formula C10H13N5O4
4 Molecular Weight 267.2413
5 IUPAC Name 1-[(2R,4S,5S)-4-azido-5(Hydroxy-methyl)oxolan-2-
yl]-5-methyl-1,2,3,4,-tetra hydroxy pyrimidine-2-
,4dione.
6 Chemical
Structure
ZIDOVUDINE
7 Half Life 0.5-3 hours
8 Dosage Form Tablet, Capsule etc.
9 Max.Daily dose 600mg/day
10 Solubility (mg/ml) 10-50 gm/L at 170C Soluble in water.
11 pKa 9.96
12 Melting pt. 106-1120C
13 Protein Binding 30-38%
14 Bioavailability 52-75%
15 Absorption After oral administration it is rapidly absorb through
gastrointestinal tract.
16 Distribution Zidovudine is extensively distributed. Binding to
plasma protein is low, less than 38%. Apparent Vd
is 1.6 L/kg.
17 Metabolism Hepatic metabolism. Major metabolites are 3′-azido-
3′-deoxy-5′-O-beta-D-glucopyranuronosylthymidine
(GZDV) and 3′-amino-3′-deoxythymidine (AMT).
18 Excretion Primarily eliminated by hepatic metabolism.
Elimination half-life is 0.5 to 3 h. GZDV (74%) and
zidovudine (14%) are recovered in the urine. Renal
Cl is 0.34 l/h/kg.
19 Mechanism Of
Action
 It is a reverse transcriptase inhibitor.
 The drug enters the host cell by diffusion and is
phosphorylated by cellular thymidine kinase.
 It then converts monophosphate into di and tri-
phosphate.
 This zidovudine triphosphate competitively
inhibit reverse transcriptase.
20 Indication In combination with other antiretroviral agents for
the treatment of HIV-1 infections; prevention of
maternal-fetal HIV-1 transmission.
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5. POLYMER AND EXCIPIENT PROFILE
5.1. HYDROXYPROPYL METHYLCELLULOSE70,71,73&80:
Table No. 5.1. Polymer Profile of Hydroxypropyl Methyl Cellulose.
Synonyms Cellulose, hydroxypropyl methyl ether, HPMC, methocel,
metolose
Chemical
Formula
HPMC is a partially o-methylated and o-(2-
hydroxypropylated) cellulose. It is available in several
grades, vary in viscosity and extent of substitution.
Structural
Formula
Solubility Soluble in cold water, forming a viscous colloidal solution,
practically insoluble in chloroform, ethanol, and ether, but
soluble in mixture of ethanol and dichloromethane, and
mixture of methanol and dichloromethane.
Molecular Weight 100 – 150000
Description HPMC is an odorless and tasteless, white or creamy white
colored fibrous or granular powder.
Functional
Category
Coating agent, film-former, stabilizing agent, suspending
agent, tablet binder, and viscosity increasing agent.
Stability and
Storage
Conditions
HPMC is a stable material although it is hygroscopic after
drying. Solutions are stable between pH 3-11. Increasing
temperature reduces the viscosity of solutions. It undergoes
a reversible sol to gel transformation upon heating and
cooling respectively. Stored in a well closed container, in a
cool, dry place.
Incompatibilities It is incompatible with some oxidizing agent. Since it is
nonionic, it will not complex with metallic salts and ionic
organics to form insoluble precipitates.
Safety It is generally regarded as a nontoxic and non-irritant
material although excessive oral consumption may have a
laxative effect.
Applications
HPMC is widely used in oral and topical pharmaceutical
formulations. In oral products it is primarily used as a tablet
binder, film coating and as an extended release tablet
matrix. Concentration between 2-5% w/w may be used as a
binder either in wet or in dry granulation process. High
viscosity grades may be used to retard the release of water
soluble drugs from a matrix. Lower viscosity grades are
used in aqueous film coating while higher viscosity grades
are used with organic solvents.
5.2. MICROCRYSTALLINE CELLULOSE71,73&80:
Table No. 5.2 Excipient Profile of Microcrystalline Cellulose.
Synonyms Celex, cellulose gel, Celphere, Emocel, and Pharmacel.
Molecular Weight 36000
Functional
Category
Tablet and capsule diluent.
Description Microcrystalline cellulose is purified, partially
depolymerized cellulose that occurs as a white, odorless,
tasteless, crystalline powder composed of porous particles.
It is commercially available in different particle sizes and
moisture grades having different properties and
applications.
Solubility slightly soluble in 5% w/v sodium hydroxide solution but
practically insoluble in water, dilute acids and most organic
solvents.
Stability and
storage conditions
It is stable, hygroscopic material The bulk material should
be stored in a well closed container in a dry, cool, place.
Incompatibility Incompatible with strong oxidizing agents.
Safety It is widely used in oral pharmaceutical formulations and
food products. It is generally regarded as a nontoxic and
non-irritant material.
Applications Microcrystalline cellulose is widely used in
pharmaceuticals, primarily as a binder / diluent in oral
tablet and capsule formulation. It is used in both wet
granulation and direct compression processes. In addition
to its use as binder / diluent, also be used as lubricant and
disintegrant agent in tableting.
5.3. POLY VINYL PYROLIDONE (PVP)71,73&80:
Table No. 5.3. Polymer Profile of Polyvinyl Pyrrolidone.
Synonyms Povidone, polyvinylpyrrolidone, PVP, kollidone, and
plasdone.
Chemical
formula
1-ethenyl-2-pyrrolidinone homopolymer. (C6H9NO)n
Molecular weight 2500-3000000.
Description It is white to creamy white, odorless or almost odorless,
hygroscopic powder
Functional
category
Tablet binder, suspending or viscosity increasing agent
Solubility Readily soluble in water, organic solvents including
monohydric (ethanol, methanol) and polyhydric alcohols,
acids, esters, ketones, and chloroform
Stability and
storage
conditions
Aqueous solutions are susceptible to growth of molds and
consequently required the addition of suitable
preservatives.
Incompatibility It forms molecular adducts in solution with sulfathiazole,
sodium salicylate, salicylic acid, phenobarbital, tannin, and
other compounds
Safety Chemically, PVP is inert and nontoxic. It does not irritate
the mucous membrane of rabbit eyes, antigenic property
and does not interfere in antibody formation studies.
Applications Carrier for drug, dispensing agent, suspending or viscosity
builder, tablet binder, tablet diluents and coating agent.
5.4. MAGNESIUM STEARATE71,73&80:
Table No. 5.4. Excipient Profile of Magnesium Stearate.
Synonyms: Magnesium octadecanoate, octadecanoic acid, magnesium
salt, stearic acid, and magnesium salt.
Chemical
Formula:
C36H70MgO4.
Molecular weight 591.34
Functional
Category
Tablet and capsule lubricant.
Description Magnesium stearate is a fine, white, precipitated or milled,
impalpable powder of low bulk density, having a faint odor
of stearic acid and a characteristic taste. The powder is
greasy to the touch and readily adheres to the skin.
Solubility Practically insoluble in ethanol, ether, and water, slightly
soluble in warm benzene and warm ethanol.
Stability and
storage conditions
Magnesium stearate is stable and should be stored in a well
closed container in a cool, dry place.
Incompatibilities Incompatible with strong acids, alkalis, and iron salts.
Avoid mixing with strong oxidizing materials. Magnesium
stearate cannot be used in products containing aspirin,
some vitamins, and most alkaloidal salt.
Applications Magnesium stearate is widely used in cosmetics, foods, and
pharmaceutical formulations. It is primarily used as a
lubricant in capsule and tablet manufacture at
concentrations between 0.25% and 5.0% w/w. It is also
used in barrier creams.
5.5. COLLOIDAL SILICON DIOXIDE71,73&80:
Table No. 5.5. Excipient Profile of COLLOIDAL SILICON DIOXIDE .
Synonyms Aerosil, colloidal anhydrous silica, anhydrous silicic acid,
silicic anhydride, silicon dioxide fumed.
Chemical formula SiO2
Description Light, loose, bluish-white coloured, odorless, tasteless,
nongritty amorphous powder
Functional
category
Adsorbent, anticacking agent, emulsion stabilizer, glidant,
Suspending agent, tablet disintegrant, thermal stabilizer,
Viscosity increasing agent.
Solubility Practically insoluble in organic solvents, water and
acids. Soluble in hot solutions of alkali hydroxide.
Stability and
storage
It should be stored in a well-closed container.
Safety It should not be administered parenterally
Applications It is used as glidant in tabletting, to stabilize emulsions and
as a thixotropic thickening agent, suspending agent in gels
and semisolid preparations, to promote particulate
suspension in aerosols. It is also used tablet disintegrant and
adsorbent dispersing agent for liquids in powders. It is
frequently added to suppository formulations containing
lipophilic excipients to increase viscosity, prevent
sedimentation during molding, and decrease the release rate.
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6. PLAN OF WORK
PHASE - I
 Preformulation studies
 Preparation of calibration curve.
 Drug characterisation
 Drug Excipients compatibility Studies(FTIR)
 Bulk density
 Tapped density
 Compressibility index
 Angle of repose
 Hausner’s ratio
PHASE – II
 Preparation of bilayer tablets by direct compression method.
PHASE – III
 Evaluation of prepared tablets
 Appearance
 Hardness
 Weight variation test
 Friability
 Thickness
 Assay
 Dissolution Study by using Phosphate Buffer pH 6.8.
 Kinetic study for the best formulation.
 Stability studies as per ICH guideline for the best formulation.
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7. MATERIALS AND EQUIPMENTS
7.1. MATERIAL (DRUG, POLYMER AND CHEMICALS):
Table No 6.1. Name of the Materials (Drug, Polymers and chemicals) and
suppliers.
Sr. No. Name of the Ingredients Name of the Suppliers
1 Lamivudine (API) Lupin Research Park, Pune.
2 Zidovudine (API) Wockhardt Pharmaceuticals Pvt.
Ltd, Aurangabad.
3 Hydroxypropylmethylcellulose K 100 M Themis Research lab, Mumbai
4 Hydroxypropylmethylcellulose K 15 M Themis Research lab, Mumbai
5 Aerosil Themis Research lab, Mumbai
6 Magnesium stearate Research lab, Mumbai.
7 Microcrystalline Cellulose Themis Research lab, Mumbai
8 Polyvinyl Pyrrolidone (K-30) Research lab, Mumbai.
9 Red oxide of Iron Themis Research lab, Mumbai
10 Methanol Sisco research lab, Mumbai
11 Potassium dihydrogen phosphate Research lab, Mumbai.
12 Sodium hydroxide Research lab, Mumbai.
13 Potassium bromide Research lab, Mumbai.
14 Hydrochloric Acid Research lab, Mumbai.
15 Potassium Chloride Research lab, Mumbai.
6.2. EQUIPMENTS:
Table No. 6.2. Name of Equipment and Manufacturer.
Sr.
No.
Name of Equipments Name of the Manufacturer
1 Rotary tablet compression machine Karnavati engineers pvt.ltd, Mumbai(Model: MINI PRESS-II MT).
2 USP Tablet Dissolution Apparatus(Type II)
Electrolab (Model:TDT-06P,
Mumbai).
3 HPLC Waters 2965, Shimadzu, Japan.
4 Hardness Tester Pfizer, Inlap ltd, Mumbai
5 Electronic balance Shimatzu, Japan (Model: AUY220).
6 Roche friability tester Lab India, Mumbai, (Model: FT1020).
7 pH meter Lab India, Mumbai, (Model: GMPH).
8 UV- Spectrophotometer. Jasco, Japan (Model: V-530 & V-630).
9 Rotary Shaker Remi instruments, vasai.
10 FT-IR spectrophotometer Shimadzu (Model: FTIR-8400S),Japan.
11 Tap density tester Lab India, Mumbai.(Model:TD1025).
12 Melting Point apparatus VEEGO, Mumbai. (Model: VMP-D).
Chapter VIII
Methodology
8. METHODOLOGY
8.1.1 Preparation of 0.2 M potassium dihydrogen phosphate62:
0.2 M potassium dihydrogen phosphate was prepared according to IP 1996.
A quantity of 27.2 gm of potassium dihydrogen phosphate was dissolved in water
and make up the volume to 1000 ml using water.
8.1.2 Preparation of 0.2 M NaOH62:
0.2 M NaOH prepared by dissolving 8 gm of NaOH in to water and make up
the volume to 1000 ml using water.
8.1.3 Preparation of phosphate buffer pH 6.862:
The phosphate buffer pH 6.4 prepared according to IP 1996 by mixing the 50
ml of 0.2 M potassium dihydrogen phosphate and 39.1 ml of 0.2 M NaOH and make
up the volume to 200 ml using water.
Calibrations curve of Lamivudine in Phosphate buffer pH 6.8:
8.1.4 Procedure62:
An accurately weighed required quantity of Lamivudine was dissolved in
phosphate buffer pH 6.8 to obtain a solution having known concentration of 5, 10,
15, 20 and 25 μg/ml.. Then absorbance of Lamivudine was determined at 270 nm.
The calibration curve is shown in Figure No 9.1 and absorbance of different
concentration of Lamivudine is shown in Table No 9.1.
8.1.5 Scanning of Lamivudine in phosphate buffer pH 6.862:
The absorption maxima of the standard solution were scanned between 200-
400 nm on JASCO UV V-630 spectrophotometer. The absorption maxima were
found to 270 nm.
8.2 Drug characteristics62 :
8.2.1 Appearance, colour:
The sample obtained was examined for its appearance and colour.
8.2.2 Solubility:
The solubility of obtained compound was determined in acetone, methylene
chloride, methanol, alkali hydroxide and water.
8.2.3 Identification test:
About 2 mg of drug was dissolve in methanol and diluted to 100 ml with the
same solvent and examined between 220 nm- 350nm, the solution shows two
absorbance maxima at 226 nm & 270 nm. The ratio of the absorbance was measured
at maxima 226 nm to that 270 nm; it was must be in between 2.0 to 2.4.
8.2.4 Assay62:
Assay or percentage purity of Lamivudine is done by UV method.
8.2.5 Melting point63:
The sample obtained was characterized for melting point of the substance.
The melting point was determined by introducing amount of substance in the
capillary attached to graduated thermometer and constant heat was applied with the
assembly suspended in the paraffin bath. The drug sample was tested in temperature
range 100-2000c and teat which drug melts was noted.
8.2.6 UV-Visible spectroscopy63:
The Lamivudine was dissolved in methanol and resultant solution was
scanned between 200-400 nm to determine its absorption maxima.
8.2.7 FT-IR spectroscopy63&69:
FT-IR spectrum of drug sample was recorded as potassium bromide (KBr)
pellets at resolution of 4cm-1 for its authentication and to study principle peaks using
Jasco FT-IR (JAPAN) spectrophotometer. The identified peaks were compared with
the principle peaks of reported IR spectrum the sample was authenticated.
8.3 Drug – Excipients Compatibility Studies63&69:
These studies were performed in order to confirm the drug- exciepient
compatibility. These studies mainly include FTIR  given below,
8.3.1 FT-IR spectroscopy study63&69:
FT-IR spectra of pure drug, Pure HPMC K100 M & K15 of this polymer
with drug were recorded on Jasco FT-IR spectrophotometer using KBr discs. The
instrument was operated under dry air purge and the scans were collected at
scanning speed 2 mm/sec with resolution of 4 cm-1 over the region 4000-400 cm-1.
The scans were evaluated for presence of principle peaks of drug, shifting and
masking of drug peaks and appearance of new peaks due to polymer interaction. The
FT-IR spectra of pure Lamivudine, Pure HPMC K100 M, HPMC K15 M and
physical mixture are shown in Figure No 9.2, 9.3, 9.4 and 9.5.
8.4 Evaluation of powder properties2,64&67:
The powder properties include Bulk density, Tap density, Hausner ratio,
Carr’s index were determined using tap density tester (Lab India).
8.4.1 Bulk Density:
The bulk density, as a measure used to describe packing materials or
granules, was determined by transferring the accurately weighed amount of powder
sample to the graduated cylinder with the aid of a funnel.  The initial volume was
noted. Ratio of weight of the sample to the volume it occupied was calculated.
The bulk density is obtained by dividing the weight of the sample in grams
by final volume1 in cm3.
b = M / Vp ………………………………..……(8.1)
Where, b = bulk density, M = weight of sample in grams,
Vp = final volumes of Powder in cm3.
8.4.2 Tap Density:
Weighed powder sample was transferred to a graduated cylinder and
was placed on the tapped density test apparatus, was operated for a fixed number of
taps (100).  The tapped density was determined as the ratio of weight of sample to
tapped volume.
The Tap density is obtained by dividing the weight of the sample in grams by
final Tap volume in cm3
T = M / VT ………………………………….….…(8.2)
Where,
T = Tap density
M = weight of sample in grams
VT = final Tap volumes of Powder in cm3.
4.4.3 Angle of repose ():
A funnel was fixed at a particular height on a burette stand. A graph paper
was placed below the funnel on the table. The powdered drug passed through the
funnel until it forms a pile. The radius of the pile was noted down. Angle of repose
of the powder material was calculated using the formula.
The frictional forces in a loose powder can be measured by the angle of
repose(). This is the maximum angle possible between the surface of a pile of
powder and the horizontal plane and it is given as,
Tan  = h / r
 = tan-1[h /r]…………………………(8.3)
Where,
 =the angle of repose
h = the height in cm
r = the radius.
The powder mixture was allowed to flow through the funnel fixed to a
stand at definite height. The angle of repose was then calculated by measuring the
height and radius of the heap of powder formed.
Table No.8.1 : Angle of Repose
Sr. No. Flowability Angle of Repose
1 Excellent 25 - 300
2 Good 30 - 350
3 Fair 35 - 370
4 Poor 37 - 450
5 Very poor Above 450
8.4.4Carr’s index:
The Carr’s index is determined from the tapped density and poured density
(bulk density) as per the formula given below.
Carr’s index (%)   =         Tapped density- poured density
----------------------------------------- X 100……… (8.4)
Tapped density
Table No.8.2:Carr’s index
Carr’s index % Type of flow
5 - 15 Excellent
12 – 18 Good
18 – 23 Fair to passable
23 – 35 Poor
35 – 38 Very poor
>40 Extremely poor
8.4.5 Hausner ratio:
Hausner ratio is determined from the ratio of tapped density to poured density
using formula given below,
Tapped density
Hausner ratio = -------------------------------- ………………….. (8.5)
Poured density
B] FOR ZIDOVUDINE
8.1.1. Calibrations curve of Zidovudine in Phosphate buffer pH 6.862:
8.1.2.5 Procedure:
An accurately weighed quantity of Zidovudine was dissolved in phosphate
buffer pH 6.8 to obtain a solution having known concentration of 5, 10, 15, 20 and
25 μg/ml. Then absorbance of Zidovudine was determined at 267 nm. The
calibration curve is shown in Figure No. 9.6 and absorbance of different
concentration of Zidovudine is shown in Table No. 9.4.
8.1.1.4 Scanning of Zidovudine in phosphate buffer pH 6.863&69:
The absorption maxima of the standard solution were scanned between 200-
400 nm on JASCO UV V-630 spectrophotometer. The absorption maxima were
found to 267 nm.
8.2 Drug characteristics61,67&72 :
8.2.1 Appearance, colour:
The sample obtained was examined for its appearance and colour.
8.2.2 Solubility:
The solubility of obtained compound was determined in acetone, methylene
chloride, methanol, alkali hydroxide and water.
8.2.3 Identification test63:
About 2 mg of drug was dissolve in methanol and diluted to 100 ml with the
same solvent and examined between 220 nm- 350 nm, the solution shows two
absorbance maxima at 226 nm & 267 nm. The ratio of the absorbance was measured
at maxima 226 nm to that 267 nm; it was must be in between 2.0 to 2.4.
8.2.4 Assay61:
Assay or percentage purity of Zidovudine is done by UV method.
8.2.5 Melting point63:
The sample obtained was characterized for melting point of the substance.
The melting point was determined by introducing amount of substance in the
capillary attached to graduated thermometer and constant heat was applied with the
assembly suspended in the paraffin bath. The drug sample was tested in temperature
range 100-2000c and teat which drug melts was noted.
8.2.6 UV-Visible spectroscopy63&69:
The Zidovudine was dissolved in methanol and resultant solution was
scanned between 200-400 nm to determine its absorption maxima.
8.3 Drug – Excipients Compatibility Studies63&69:
These studies were performed in order to confirm the drug- exciepient
compatibility. These studies mainly include FTIR given below,
8.3.1 FT-IR spectroscopy study63&69:
FT-IR spectra of pure drug, Pure HPMC K100 M & physical mixtures of this
polymer with drug were recorded on Jasco FT-IR spectrophotometer using KBr
discs. The instrument was operated under dry air purge and the scans were collected
at scanning speed 2 mm/sec with resolution of 4 cm-1 over the region 4000-400 cm-1.
The scans were evaluated for presence of principle peaks of drug, shifting and
masking of drug peaks and appearance of new peaks due to polymer interaction. The
FT-IR spectra of pure Zidovudine, Pure HPMC K100 M, HPMC K15 M and
physical mixtures are shown in Figure No 9.7, 9.8, 9.9 and 9.10.
8.4 Evaluation of powder properties62,64,72&74:
The powder properties include Bulk density, Tap density, Hausner ratio,
Carr’s index were determined using tap density tester (Lab India).
8.4.1 Bulk Density:
The bulk density, as a measure used to describe packing materials or
granules, was determined by transferring the accurately weighed amount of powder
sample to the graduated cylinder with the aid of a funnel.  The initial volume was
noted. Ratio of weight of the sample to the volume it occupied was calculated.
The bulk density is obtained by dividing the weight of the sample in grams
by final volume1 in cm3.
B = M / Vp ………………………………..……(8.6)
Where,     B = bulk density      M = weight of sample in grams
Vp = final volumes of Powder in cm3.
8.4.2 Tap Density:
Weighed powder sample was transferred to a graduated cylinder and was
placed on the tapped density test apparatus, was operated for a fixed number of taps
(100).  The tapped density was determined as the ratio of weight of sample to tapped
volume.
The Tap density is obtained by dividing the weight of the sample in grams by
final Tap volume in cm3
T = M / VT ………………………………….….…(8.7)
Where,
T = Tap density
M = weight of sample in grams
VT = final Tap volumes of Powder in cm3.
8.4.3 Angle of repose ():
A funnel was fixed at a particular height on a burette stand. A graph paper
was placed below the funnel on the table. The powdered drug passed through the
funnel until it forms a pile. The radius of the pile was noted down. Angle of repose
of the powder material was calculated using the formula.
The frictional forces in a loose powder can be measured by the angle of
repose . This is the maximum angle possible between the surface of a pile of
powder and the horizontal plane and it is given as,
Tan  = h / r,
 = tan-1[h /r]……………………………… (8.8)
Where,
 = the angle of repose
h = the height in cm
r = the radius.
The powder mixture was allowed to flow through the funnel fixed to a stand
at definite height. The angle of repose was then calculated by measuring the height
and radius of the heap of powder formed.
Table No.8.3: Angle of Repose
Sr. No. Flowability Angle of Repose
1 Excellent 25 - 300
2 Good 30 - 350
3 Fair 35 - 370
4 Poor 37 - 450
5 Very poor Above 450
8.4.4 Carr’s index:
The Carr’s index is determined from the tapped density and poured density
(bulk density) as per the formula given below,
Tapped density- poured density
Carr’s index (%) = ------------------------------------------ X 100…………(8.9)
Tapped density
Table No.8.4: Carr’s index
Carr’s index % Type of flow
5 - 15 Excellent
12 – 18 Good
18 – 23 Fair to passable
23 – 35 Poor
35 – 38 Very poor
>40 Extremely poor
8.4.5 Hausner ratio:
Hausner ratio is determined from the ratio of tapped density to poured
density using   formula given below.
Tapped density
Hausner ratio = --------------------- ………………….. (8.10)
Poured density
8.5 Preparation of Lamivudine And Zidovudine Controlled release Bilayer
Tablets53&54:
The tablets were prepared by direct compression technique. Before
blending of drug and other Excipients, they were sifted through sieve no. 40 to
remove any large particles. Drugs and other Excipients were blended for 10 mins.
Then, subsequently this powder mixture was blended for 5 mins. with magnesium
stearate. This mixture was directly compressed to get the tablets.
a) Preparation of Lamivudine controlled release layer:
DOSE CALCULATION    (Theoretical Release Profile)
Total drug of Lamivudine for controlled release formulation was calculated
by the following equation using available pharmacokinetic data..
Dt= Dose(1+0.639Xt/t1/2)
Where, Dt=Total dose of Drug, Dose= Dose of immediate release part
(50mg), t= time (hours) during which the controlled release is desired (12hours),
t1/2= half-life of the drug( 7 Hours).
Dt=50(1+0.639X12/7)=140.5 mg
Hence, Lamivudine active 150mg taken as controlled release per tablet.
Table No.8.5: Lamivudine layer formulation.
Sr.
No.
Ingredients
(mg) LF1 LF2 LF3 LF4 LF5 LF6 LF7 LF8 LF9
1 Lamivudine 150 150 150 150 150 150 150 150 150
2 HPMC
(K100)
15 18.75 22.5 _ _ _ 7.5 9.37 11.25
3 HPMC(K15) _ _ _ 30 37.5 45 15 18.75 22.5
4 MCC 15 15 15 15 15 15 15 15 15
5 PVP 15 15 15 15 15 15 15 15 15
6 Aerosil 5 5 5 5 5 5 5 5 5
7 Mg.Stearate 5 5 5 5 5 5 5 5 5
8 Red oxide
iron
q.s q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s.
Total wt. 205 208.75 212.5 220 227.5 235 212.5 218.12 223.75
The Lamivudine controlled release layer containing uniform mixture of
Lamivudine and all excipients are sifted through 40# sieve and mixed well
for10minutes. And then lubricated with magnesium stearate (presifted through 40#),
the well-mixed powder blend were used as upper layer.
b) Preparation of Zidovudine controlled release layer.
DOSE CALCULATION    (Theoretical Release Profile)
Total drug of Zidovudine for controlled release formulation was calculated by
the following equation using available pharmacokinetic data..
Dt= Dose(1+0.639Xt/t1/2)
Where, Dt=Total dose of Drug, Dose= Dose of immediate release part
(100mg), t= time(hours) during which the controlled release is desired (12hours),
t1/2= half-life of the drug (3Hours).
Dt=100(1+0.639X12/3)= 307 mg.
Hence, Zidovudine active 300 mg taken as controlled release per tablet.
Table No. 8.6: Zidovudine Layer formulations
Sr.
No.
Ingredients
(mg) ZF1 ZF2 ZF3 ZF4 ZF5 ZF6 ZF7 ZF8 ZF9
1 Zidovudine 300 300 300 300 300 300 300 300 300
2
HPMC
(K 100) 30 37.5 45 _ _ _ 15 19 22.5
3
HPMC
(K 15) _ _ _ 60 75 90 30 37.5 45
4 MCC 20 20 20 20 20 20 20 20 20
5 PVP 20 20 20 20 20 20 20 20 20
6 Aerosil 6 6 6 6 6 6 6 6 6
7 Mg. Stearate 6 6 6 6 6 6 6 6 6
Total wt. 382 389.5 397 412 427 442 397 408.5 419.5
The controlled release layer containing uniform mixture of drug, polymers
and excipients was mixed properly with weighed amount of polymers and
Excipients. The well-mixed powder was compressed by direct Compression
technique and is used as lower controlled release layer.
c) Preparation of bilayer tablets:
Bilayer tablets were prepared by combining of two formulations of
controlled release layer. After the compression upper punch was lifted and the blend
of powder first controlled release layer was poured into the die, containing initially
compressed matrix tablet on RIMEK multi station punching machine.
8.6 Evaluation of Lamivudine and Zidovudine Controlled release Bilayer
Matrix Tablet2,62,68,72,74,77&83:
Tablets prepared from powder blends were subjected to evaluation of
properties including drug content uniformity, weight variation, tablet hardness,
friability, thickness , in vitro drug release and kinetic study etc.
8.6.1 Weight Variation:
Procedure:
Twenty tablets were selected randomly and weighed by using Electronic
balance (Shimatzu). Average weight of the tablet was determined. These tablets
were weighed individually and the weight variation was determined.
Table No.8.7: Weight Variation Tolerance for Uncoated Tablets.
Sr. No. Average  Weight  of  Tablets(mg)
Maximum Percentage Difference
Allowed (%)
1 130 or less 10
2 130 to 324 7.5
3 More than 324 5
8.6.2 Tablet hardness:
The resistance of tablets to shipping or breakage, under conditions of storage,
transportation and handling before usage depends on its hardness. The hardness of
tablet of each formulation was checked by using Pfizer hardness tester. The hardness
was measured in terms Kg/cm2.
8.6.3 Friability:
Friability was measure the tablet strength. Roche friabilator (Lab India) was
used for testing the friability using the following procedure:
Twenty tablets were weighed accurately and placed in the tumbling
apparatus that revolves at 25 rpm dropping the tablets through a distance of six
inches with each revolution. After 20min, the tablets were weighed and the
percentage loss in tablet weight was determined.
8.6.4 Thickness:
Thickness of tablet is important for uniformity of tablet size. Thickness was
measured by using Vernier Calipers. It was determined by checking ten tablets from
each formulation.
8.6.5 In vitro Drug Release studies of Lamivudine and Zidovudine Controlled
Release Matrix Bilayer Tablet35,37,41&43:
Tablets of all preliminary batches were subjected to dissolution rate studies.
In-vitro dissolution studies were carried out on dissolution apparatus
(ElectrolabModel: TDT-06P) to determine the drug release from various
formulations. The   37 ± 0.5 °C Temperature maintain throughout the study. Studies
were carried out in 900 ml of 6.8 phosphate buffer up to 12 hours at 100 rpm.
Sample measuring 10 ml were withdrawn at 1, 2, 4,6,8,10,12 hr. and immediately
replaced by equal volume of dissolution media equilibrated at the same temperature
to maintain the volume. The sample withdrawn was passed through 0.45 µm. Then
the resulting filtrate was evaluated by using HPLC. The row dissolution data
recorded was analyzed to calculate the amount of drug release and percentage
cumulative drug release at different time intervals.  The graphs of times vs. %
cumulative release were plotted.
Details of dissolution test:
Dissolution test apparatus : USP TYPE II (DTD – 06P).
Speed : 100 rpm
Stirrer : paddle type
Volume of medium : 900 ml
Aliquot taken at each time interval : 10 ml
Medium used : pH 6.8 Phosphate buffer
Temperature : 37 ± 0.5 0C
8.6.6 Assay & Uniformity of content41:
8.6.6.1 Assay By HPLC:
Apparatus:
The HPLC system was waters HPLC consisted with the pump-alliance 2695
separation module, columnphenomenex luna 5μ C18 (12) 100A,(250×4.6×i.d,5μ),
auto sampler, detector was waters 2996 and prominence diode array detector. Other
instruments used were, Melter balance AY 220, Elico pH meter LI 127, Melter
Ultrasonicatior and Millipore membrane filter. Shimadzu balance AY 220 and
sonica ultrasonic cleaner were used.
Table No.8.8: Chromatographic Condition41:
Mobile Phase Acetonitrile: water (20:80)
Column Luna 5μ C18 (12) 100A,(250×4.6×i.d,5μ).
Flow rate 1.0 ml/min.
Detection(λ max) 270 nm ( Isobestic pt.).
Column Oven Ambient.
Injection Volume 20µL(loop injector).
Run Time 10 minutes.
Methods:
Preparation of Standard solutions:
Primary stock solution concentration of Lamivudine and Zidovudine 1000
μg/ml was prepared. All measurements were made at room temperature. The
standard solutions were prepared by proper dilutions of the primary stock solution
with acetonitrile and water (20:80) to obtain working standards in the concentration
range of of Lamivudine and Zidovudine.
Sample preparation:
The tablet containing 300 mg Zidovudine and 150 mg Lamivudine were
weighed, powdered and dissolved in acetonitrile and water (20:80) made to 1000
μg/ml. The stock solution of Zidovudine and Lamivudine was suitably diluted to
give the mixture concentration of 30& 15, 45 & 30, 60 & 45, 75 & 60 and 90 &75
μg/ml for measurement. The contents were mixed thoroughly and filtered through
0.45μ membrane filter and sonicated for 20 min.
8.6.6.2 Uniformity of content41:
The drug content of ten dosage units was determined by HPLC method
which is discussed above.
8.7 Data analysis [KINETIC STUDY] 7, 81&82:
To analyze the mechanism of release and release rate kinetics of the dosage
form, the data obtained were fitted into Zero order, First order, Higuchi matrix and
korsemeyer Peppas model using PSP-DISSO – v2 software. Based on the r-value,
the best-fit model was selected.
Zero order kinetics:
Drug dissolution from pharmaceutical dosage forms that do not disaggregate
and release the drug slowly, assuming that the area does not change and no
equilibrium conditions are obtained can be represented by the following equation,
Q t = Q o + K o t…………………………………………. (8.11)
Where,
Q t = amount of drug dissolved in time t.
Q o = initial amount of the drug in the solution and
K o = zero order release constant.
First order kinetics:
To study the first order release rate kinetics, the release rate data were fitted
to the following equation,
Log Qt = log Qo + K1t/2.303……………………………….. (8.12)
Where,
Qt = the amount of drug released in time t,
Qo = the initial amount of drug in the solution,
K1 = the first order release constant.
Higuchi model81:
Higuchi developed several theoretical models to study the release of water
soluble and low soluble drugs incorporated in semisolids and/or solid matrices.
Mathematical expressions were obtained for drug particles dispersed in a uniform
matrix behaving as the diffusion media. And the equation is,
Qt = KH ·t1/2………………………….………………….. (8.13)
Where,
Qt = amount of drug released in time t,
KH = Higuchi dissolution constant.
Krosmeyer and Peppas release model82:
To study this model the release rate data are fitted to the following equation,
Mt / M ¥ = K · t n ……………………………………… (8.14)
Where,
Mt / M ¥ = the fraction of drug release,
K = the release constant,
T = the release time,
N = the diffusional coefficient for the drug release that is dependent on the
shape of the matrix dosage form.
Table No. 8.9 : Release Kinetics
Diffusion Exponent
[Release exponent(n)]
Overall solute diffusion mechanism
(Drug transport mechanism)
>0.45 Fickian diffusion
0.45<0.89 Anomalous (non-fickian) transport
0.89< 1 Case II
1< Super case II
8.8 Stability studies for the best formulation76 (As per ICH Guideline):
Stability of a pharmaceutical preparation can be defined as “the capability of
a particular formulation in a specific container/closure system to remain within its
physical, chemical, microbiological, therapeutic and toxicological specifications
throughout its shelf life.” The purpose of stability testing is to provide evidence on
how the quality of a drug substance or drug product varies with time under influence
of a variety of environmental factors such as temperature, humidity and light, and
enables recommended storage conditions, re-test periods and shelf-lives to be
established.
ICH specifications for stability study:
Long term testing: 25 0C ± 2 0C /60% RH ± 5% RH for 12 months.
Accelerated testing: 40 0C ± 2 0C /75% RH ± 5% RH for 6 months.
Procedure:
In the present study, stability studies were carried out at 400 C and 75% RH
for a specific time period up to 3 month for selected formulations. For stability
study, the tablets were sealed in aluminum packaging coated inside with
polyethylene. These sample containers were placed in desiccator maintained at 75%
RH.
NOTE: Saturated solution of sodium chloride at 400 C yields a 75% relative
humidity.
Evaluation of samples:
The samples were analyzed for the following parameters:
I. Physical evaluation:
Appearance: The samples were checked for any change in colour at every week.
Hardness: The samples were tested for hardness at every week.
II. Chemical evaluation:
Drug content: The samples were checked for drug content.
Drug release: The samples were subjected to drug release studies.
Chapter IX
Results and Discussion
9. RESULT AND DISCUSSION
PREFORMULATION STUDIES:
A] FOR LAMIVUDINE:
Calibrations curve of Lamivudine in Phosphate buffer pH 6.8:
The calibration curve of the Lamivudine was prepared in the Phosphate
buffer pH 6.8. Following Table No. 9.1 shows the absorbance at λ max 270 nm and
Figure No. 9.1 Shows the calibration curve with regression coefficient  0.9939,
slope  0.0044 and the Y intercept  +0.0048.
Table No.9.1:  Data for Standard Curve of Lamivudine.
Sr. No. Concentration(µg/ml) Absorbance at 270nm
0 0 0
1 5 0.031
2 10 0.051
3 15 0.07
4 20 0.091
5 25 0.113
Calibration Curve of Lamivudine.
Figure No. 9.1: Calibration curve Graph of Lamivudine in
pH 6.8 Phoshphate Buffer.
Physical Evaluation of Lamivudine
Appearance, colour:
The powder sample was found to be white and crystalline.
Solubility:
The Lamivudine powder was found to be freely soluble in water, methanol.
Identification Test:
The ratio of the absorbance measured at maxima 226nm to 270nm was
found. That conform the sample taken was Lamivudine.
Assay:
The obtained sample of Lamivudine was found to be 99.17% pure by
reported assay method.
Melting point:
The melting point was found to be 160-1620C.
UV-Visible spectroscopy:
The Lamivudine was dissolved in methanol shows absorbance maximum at
270nm.
COMPATIBILITY STUDIES OF DRUG AND POLYMERS:-
Figure No. 9.2: IR Spectrum of pure Lamivudine
Figure No.9.3: IR Spectrum of HPMC K 100
Figure No.9.4: IR Spectrum of HPMC K 15
Figure No.9.5: IR Spectrum of physical mixture (Lamivudine+ HPMC K 100+ HPMC K 15)
The FTIR spectra of the pure drug, excipient and physical mixture of drug and
excipient were recorded in between 400-2000 wave number (cm-1), no peak are
observed with the main drug peak. The following spectrum and table shows IR
spectrum for drug and polymer and the wave number of characteristics bands are same.
Table no.9.2: FT-IR Peak of various components:
Wave Number in
cm-1
Characteristic bands Drug Physical Mixture
1000-1300 Asymetric stretching of
Ether system
1284 1266.34
1000-1400 Asymetric stretching of
Ether system
1161 1158.85
1735-1750 Carbonyl group 1650 1651.2
3200-3400 Hydroxyl group 3319,3271 and
3197
3200, 3100
3300-3500 Amino group 3319, 3271
and 3197
3321, 3250
In FT-IR study the characteristic peak due to pure Lamivudine has appeared in
the spectra of formulation without any markable changes in the position. It indicated
that there was no chemical interaction between Lamivudine and polymer used.
EVALUATION PARAMETERS:
Table No.9.3: Evaluation of Lamivudine Blend.
±SD of means of three Determintion.
For the granules of all the formulated batches, the angle of repose was found to
be in the range of 27° to 30°, thus indicating that the flow properties were good.
Hausner’s ratio was less than 1.18 for all the batches indicating good flow properties.
Formulation
code
Angle of
repose
(n=3)
Bulk
density
g/ml
(n=3)
Tapped
density
(g/ml)
(n=3)
Compressibility
index (%)
(n=3)
Hausner’s
ratio
(n=3)
LF1 280.87”±1.20 0.466±0.002 0.542±0.012 14.02±0.92 1.16±0.07
LF2 270.95”±1.120 0.462±0.004 0.523±0.022 11.66±0.96 1.13±0.06
LF3 280.87”±1.08 0.463±0.004 0.542±0.013 14.75±0.88 1.17±0.04
LF4 270.91”±1.20 0.442±0.005 0.521±0.017 15.16±1.0 1.17±0.08
LF5 270.89”±1.14 0.431±0.003 0.501±0.015 13.9±1.12 1.16±0.05
LF6 280.79”±1.08 0.452±0.002 0.515±0.016 12.23±1.2 1.13±0.05
LF7 270.78”±1.12 0.449±0.003 0.522±0.013 13.98±1.04 1.16±0.04
LF8 280.89”±1.08 0.445±0.002 0.521±0.014 14.58±0.88 1.17±0.06
LF9 270.91”±1.10 0.462±0.004 0.524±0.013 11.83±0.98 1.13±0.07
B] FOR ZIDOVUDINE:
Calibrations curve of Zidovudine in Phosphate buffer pH 6.8:
The calibration curve of the Zidovudine was prepared in the Phosphate buffer
pH 6.8. Following Table No 9.4 shows the absorbance at λ max 267 nm and Figure No.
9.6 Shows the calibration curve with regression coefficient  0.9999 , slope  0.0393 and
the Y intercept  +0.0003.
Table No.9.4: Data for Standard Curve of Zidovudine.
Calibration Curve of Zidovudine.
Figure No.9.6: Calibration curve Graph of Zidovudine  in PH 6.8
Phoshphate Buffer.
Sr.no Concentration(μg/ml) Absorbance at 267nm
1 5 0.199
2 10 0.388
3 15 0.595
4 20 0.783
5 25 0.983
Physical Evaluation of Zidovudine:-
Appearance, colour:
The powder sample was found to be white and crystalline.
Solubility:
The Zidovudine powder was found to be sparingly soluble in water, and freely
soluble in methanol.
Identification Test:
The ratio of the absorbance measured at maxima 226nm to 267nm was found.
That conform the sample taken was Zidovudine.
Assay:
The obtained sample of Zidovudine was found to be 98.94% pure by reported
assay method.
Melting point:
The melting point was found to be 106-1120C.
UV-Visible spectroscopy:
The Zidovudine was dissolved in methanol shows absorbance maximum at
267nm.
COMPATIBILITY STUDIES OF DRUG AND POLYMERS:
Figure No.9.7: IR Spectrum of pure Zidovudine Drug.
Figure No.9.8: IR Spectrum of HPMC K 100
Figure No.9.9: IR Spectrum of HPMC K 15
Figure No.9.10: FT-IR Spectrum of Physical Mixture (Zidovudine+ HPMC K100+HPMC K15+PVP+MCC)
Table No.9.5: FT-IR Peak of various components:
Wave Number in
cm-1
Characteristic bands Drug Physical Mixture
1000-1300 Asymetric stretching of
Ether system
1284 1266.34
1000-1400 Asymetric stretching of
Ether system
1161 1158.85
1735-1750 Carbonyl group 1695 1676.7
3200-3400 Hydroxyl group 3319,3271 and
3197
3200, 3100
3300-3500 Amino group 3319, 3271
and 3197
3321, 3250
In FT-IR study the characteristic peak due to pure Zidovudine has appeared in
the spectra of formulation without any markable changes in the position. It indicated
that there was no chemical interaction between Zidovudine and polymer used.
EVALUATION PARAMETERS:
Table No.9.6: Evaluation of Zidovudine Blend.
Formulation
code
Angle of
repose
(n=3)
Bulk
density
(g/ml)
(n=3)
Tapped
density
(g/ml)
(n=3)
Compressibility
index (%)
(n=3)
Hausner’s
ratio
(n=3)
ZF1 290.81”±0.79 0.425±0.002 0.487±0.012 12.73±0.96 1.14±0.05
ZF2 280.85”±0.91 0.408±0.004 0.465±0.015 12.25±0.90 1.13±0.03
ZF3 270.83”±0.92 0.377±0.006 0.434±0.010 13.13±0.92 1.15±0.04
ZF4 280.87”±0.87 0.363±0.003 0.408±0.013 11.02±0.94 1.12±0.07
ZF5 270.91”±0.84 0.370±0.003 0.418±0.011 11.48±0.91 1.12±0.04
ZF6 290.93”±0.78 0.368±0.002 0.422±0.014 12.79±1.04 1.14±0.01
ZF7 280.85”±0.87 0.362±0.006 0.414±0.013 12.56±0.98 1.14±0.03
ZF8 290.86”±0.84 0.364±0.005 0.416±0.012 12.5±0.94 1.14±0.04
ZF9 280.81”±0.88 0.360±0.007 0.412±0.017 12.62±0.96 1.14±0.02
±SD of mean of three Determination
For the granules of all the formulated batches, the angle of repose was found to
be in the range of 250 to 300, thus indicating that the flow properties were good.
Hausner’s ratio was less than 1.25 for all the batches indicating good flow properties.
POST-FORMULATION STUDY:-
The Tablet from each formulation were evaluated for Uniformity in Drug
content, Average weight, Thickness, Hardness  and result are reported in Table No 9.7 .
The tablets showed good weight uniformity as indicated by the low value of Relative
Standard Deviation (RSD< 1%), The Tablet thickness were found to range from 3.90 ±
0.01 mm to 4.00 ± 0.01 mm, The Drug content uniformity of the Tablet was found to
comply with the official specification, as the assay value found to in range between
98.65 ± 0.62 to 101.28 ±1.37 of the theoretical value. The tablet Hardness varied from
6.0 ±0.2 to 6.5 ± 0.4. The tablets passed the friability test, as all the batches were within
the pharmacopoeial limit (F< 1%).
Table No.9.7: Various properties of Tablet including average weight, Thickness,
Hardness, Friability & % Drug Content.
Batch
code
Average
weight (mg)
[n=20]
Thickness
(mm)
[n=3]
Hardness
Kg/cm2
[n=3]
%
Friability
Percentage Drug Content [n=3]
Lamivudine Zidovudine
LF1+ZF1 587±4.89 3.90± 0.01 6.5 ± 0.3 0.18 99.54 ±0.78 98.61 ± 0.34
LF2+ZF2 598.25±4.75 3.90± 0.02 6.0 ± 0.6 0.23 100.85 ± 1.03 99.1 ± 0.92
LF3+ZF3 609.5±3.76 3.94± 0.02 6.5 ± 0.2 0.23 98.85 ± 0.36 99.22 ± 0.78
LF4+ZF4 632±4.74 3.94± 0.01 6.0 ± 0.2 0.22 101.07 ± 1.12 100.05 ± 0.97
LF5+ZF5 654.5±3.85 3.96±0.02 6.5 ± 0.4 0.19 99.14 ± 1.07 98.93 ± 0.54
LF6+ZF6 677±2.85 4.00± 0.01 6.0 ± 0.3 0.29 101.19 ± 0.93 99.87 ± 0.76
LF7+ZF7 609.5±4.07 3.94± 0.01 6.0 ± 0.2 0.28 98.65± 0.62 99.45 ± 0.45
LF8+ZF8 626.62±4.36 3.94± 0.02 6.5 ± 0.2 0.34 100.25 ±1.51 101.12 ± 0.1.04
LF9+ZF9 643.25±3.92 3.98± 0.01 6.0 ± 0.4 0.27 101.28 ±1.37 100.12 ± 0.98
In Vitro Evaluation of Controlled release Bilayer Matrix Tablet:
A] In vitro Dissolution Studies of Lamivudine Layer from formulation LF1-LF9 in
Phosphate buffer pH 6.8.
Table No.9.8:
Time
(Hrs.)
Cumulative Percentage Drug release
LF1 LF2 LF3 LF4 LF5 LF6 LF7 LF8 LF9
0 0 0 0 0 0 0 0 0 0
1 25.02 24.44 23.03 23.22 20.32 18.55 22.65 21.18 20.25
2 39.12 37.32 36.13 34.19 32.31 30.43 35.14 33.45 32.61
4 54.21 50.11 49.21 49.26 48.76 44.05 49.31 48.27 45.36
6 67.03 62.15 59.34 64.47 62.55 60.16 64.45 62.65 61.72
8 83.43 81.33 80.65 77.13 74.45 71.48 77.67 73.71 71.88
10 97.04 94.23 92.12 93.34 85.56 82.71 88.12 84.29 80.36
12 - - - - 97.79 93.09 96.35 95.09 91.73
Figure No 9.11: Cumulative Percentage Drug release of formulation LF1-LF9.
B] In vitro Dissolution Studies of Zidovudine Layer from formulationZF1-ZF9 in
Phosphate buffer pH 6.8:
Table No.9.9:
Time
(Hrs.)
Cumulative Percentage Drug release
ZF1 ZF2 ZF3 ZF4 ZF5 ZF6 ZF7 ZF8 ZF9
0 0 0 0 0 0 0 0 0 0
1 27.44 26.12 25.78 26.42 24.29 20.67 25.7 24.30 22.17
2 40.16 39.47 36.39 39.11 37.43 30.82 38.38 36.42 33.72
4 55.29 51.37 52.76 55.19 52.13 45.39 54.53 52.34 51.14
6 68.41 66.03 62.47 67.34 65.82 59.51 67.71 64.19 61.32
8 82.62 80.18 79.48 80.72 76.55 71.63 81.37 75.24 72.63
10 97.07 95.37 93.17 94.21 88.38 84.26 91.32 86.62 84.27
12 _ _ _ _ 98.68 92.09 96.05 94.17 93.63
Fig No 9.12: Cumulative Percentage Drug release of formulation  ZF1-ZF9.
HPLC STUDY FOR PURE LAMIVUDINE AND ZIDOVUDINE DRUG:
Figure No.9.13: Chromatogram of Pure Lamivudine and Zidovudine  Drug.
Table No.9.10: Data obtained from pure Lamivudine and Zidovudine Drug.
HPLC STUDY FOR BEST FORMULATION (LF5+ZF5):
Figure No.9.14: Peak obtained after 1hr dissolution.
Table No.9.11:Data obtained from HPLC after 1hr dissolution.
Figure No.9.15: Peak obtained after 2hr dissolution.
Table No.9.12: Data obtained from HPLC after 2hr dissolution.
Figure No.9.16: Peak obtained after 4hr dissolution.
Table No.9.13: Data obtained from HPLC after 4hr dissolution.
Figure No.9.17: Peak obtained after 6hr dissolution.
Table No.9.14: Data obtained from HPLC after 6hr dissolution.
Figure No.9.18: Peak obtained after 8hr dissolution.
Table No.9.15: Data obtained from HPLC after 8hr dissolution.
Figure No.9.19: Peak obtained after 10hr dissolution.
Table No.9.16: Data obtained from HPLC after 10hr dissolution.
Figure No.9.20: Peak obtained after 12hr dissolution.
Table No.9.17: Data obtained from HPLC after 12hr dissolution.
KINETIC STUDY OF LAMIVUDINE AND ZIDOVUDINE BILAYER
TABLET (LF5+ZF5):
A] FOR LAMIVUDINE LAYER FORMULATION (LF5):
Table No.9.18:
Time
in
Hrs. √Time
(Hrs.)
Log
Time
(Hrs.)
Cumulative
Percentage
Drug
Release
Log
Cumulative
Percentage
Drug
Release
Percentage
Drug
Remained
Log
Percentage
Drug
Remained
0 0.00 0.00 0 0 100 2.00
1 1.0 0.00 20.32 1.3080 79.68 1.9013
2 1.41 0.3010 32.31 1.5093 67.69 1.8305
4 2.00 0.6021 48.76 1.6880 51.24 1.7096
6 2.45 0.7782 62.55 1.7962 37.45 1.5734
8 2.83 0.9031 74.45 1.8718 25.55 1.4073
10 3.16 1.00 85.56 1.9322 14.44 1.1595
12 3.46 1.0792 97.79 1.9902 2.21 0.3443
Zero Order Plot
Figure No.9.21: Zero Order Plot
First Order Plot
Figure No.9.22: First Order Plot
Higuchi Plot
Figure No.9.23: Higuchi Plot
Korsmeyer peppas plot
Figure No.9.24: Korsmeyer peppas plot.
Table No.9.19: Kinetic values obtained from Lamivudine Layer (LF5).
Mechanism of Drug Release
In order to understand the complex mechanism of drug releasevfrom the
matrix system, the in vitro release rate were fitted to Korsmeyer-peppas model and
interpretition  of release component value (n) enlighten in understanding the release
mechanism from the dosage form. The release exponent value (n) thus obtained was
0.815. The LF5 formulation exhibited anomalous (non-fickian) diffusion
mechanism.
These formulations are also showed as highest R2 values of zero order
kinetics indicating the amount of drug from the matrix system were by both
diffusion and erosion.
Formuation
Zero
order
plot
R2
First
order
plot
R2
Higuchi
R2
Korsmeyer-
Peppas Plot
R2
N
Mechanism
of Drug
Release
LF5 0.9888 0.859 0.9903 0.6419 0.815
Zero order
non fickian
diffusion.
B] FOR ZIDOVUDINE LAYER FORMULATION (ZF5):
Table No. 9.20:
Time
in Hrs. √Time
(Hrs.)
Log Time
(Hrs.)
Cumulative
Percentage
Drug
Release
Log
Cumulative
Percentage
Drug
Release
Percentage
Drug
Remained
Log
Percentage
Drug
Remained
0 0.00 0.00 0 0 100 2.00
1 1.0 0.00 24.29 1.3854 75.71 1.8791
2 1.41 0.3010 37.43 1.5742 62.57 1.7963
4 2.00 0.6021 52.13 1.7170 47.87 1.6800
6 2.45 0.7782 65.82 1.8183 34.18 1.5337
8 2.83 0.9031 76.55 1.8839 23.45 1.3701
10 3.16 1.00 88.38 1.9463 11.62 1.0652
12 3.46 1.0792 98.68 1.9942 1.32 0.1205
Zero order plot
Figure No.9.25: Zero order plot
First order plot
Figure No.9.26: First order plot
Higuchi Plot
Figure No. 9.27: Higuchi Plot
Korsmeyer peppas plot
Figure No.9.28: Korsmeyer peppas plot
Table No.9.21: Kinetic values obtained from Zidovudine Layer (ZF5).
Mechanism of Drug Release
In order to understand the complex mechanism of drug releasevfrom the
matrix system, the in vitro release rate were fitted to Korsmeyer-peppas model and
interpretition  of release component value (n) enlighten in understanding the release
mechanism from the dosage form. The release exponent value (n) thus obtained was
0.863. The ZF5 formulation exhibited anomalous (non-fickian) diffusion
mechanism.
These formulations are also showed as highest R2 values of zero order
kinetics indicating the amount of drug from the matrix system were by both
diffusion and erosion.
Formulation Zero order
plot
R2
First
order plot
R2
Higuchi
R2
Korsmeyer-
Peppas Plot
R2
N Mechanism
of Drug
Release
ZF5 0.9862 0.8412 0.9966 0.6004 0.863 Zero order
non fickian
diffusion.
STABILITY STUDIES (AS PER ICH GUIDELINES)
The fabricated controlled release formulation (finely selected LF5+ZF5) was
subjected to stability studies at 40oc±2oc/75%RH±5% for 90 days. The product was
evaluated for appearance and hardness for every 10 days. Drug content and drug
release studies were conducted as per planned scheduled as above.
Table No.9.22: Showing drug content, hardness and friability study.
A] In vitro Dissolution studies For Lamivudine:
Table No.9.23:
Time in Hrs. Cumulative Percentage Drug release
1st Month 2nd Month 3rd Month
0 0 0 0
1 20.27 20.01 19.76
2 32.28 32.10 31.88
4 48.71 48.45 48.14
6 62.50 62.23 61.97
8 74.41 74.20 73.90
10 85.54 85.38 85.13
12 97.71 97.53 97.25
Duration Drug content (%) Hardness
Kg/cm2
Friability
%Lamivudine Zidovudine
After one month 99.52 99.78 6.5±0.14 0.19
After two month 99.33 99.61 6.5±0.17 0.17
After three month 99.20 99.39 6.5±0.12 0.17
Fig No.9.29: Cumulative Percentage Drug release of formulation LF5 after
1st,2nd& 3rd month.
B] In vitro Dissolution studies For Zidovudine:
Table No.9.24:
Time in Hrs. Cumulative Percentage Drug release
1st Month 2nd Month 3rd Month
0 0 0 0
1 24.23 24.11 23.88
2 37.41 37.18 36.96
4 52.10 52.03 51.81
6 65.74 65.64 65.30
8 76.51 76.32 76.13
10 88.34 88.16 88.14
12 98.60 98.43 98.19
Figure No.9.30: Cumulative Percentage Drug release of formulation ZF5
after 1st, 2nd& 3rd month.
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10. SUMMARY
Literature survey reveals that the various works has been done on the both
synthetic and non-synthetic polymers. The successful preparations of the swellable
matrices depend on the availability of proper selection of polymer. The present
investigation was undertaken with the aim to formulate and in vitro evaluate
Lamivudine and Zidovudine controlled release bilayer matrix tablets by using
HPMC K 100 and HPMC K 15.
In the present work direct compression method was employed to prepare
tablets.  Micro-crystalline cellulose was selected as diluent. HPMC K 100 AND
HPMC K 15 was used alone and combination as a rate controlling polymer in
different concentration. Polyvinylpyrolidone was used as a binder. Magnesium
stearate and aerosil were selected as lubricant and glidant respectively. Tablets
were compressed individually using biconcave 8mm punches in Rimek multi
station rotary compression machine.
Pre-compressional parameters like angle of repose, percentage
compressibility and Hausner’s ratio studies indicated that most of the formulation
showed fair and good flow properties. These all pre-compression parameters were
found within the limits. FTIR study was performed for the drug and excipient
compatibility. From that study it showed there was no significant change in the
peak value, which means there was no interaction between drug and excipients.
Post-compressional parameters like hardness, friability, drug content,
dissolution studies were done for all formulation. All post-compressional parameters
were found within the limits. From that studies I have selected best formulation and
performed kinetic and stability studies.
The stability study for the best formulation (LF5+ZF5) were carried out by
keeping the tablets at 450c± 20c/ 75% RH for 90 days. All the parameters were found
to be within the limits after 90 days.
Investigation of the order and mechanism of drug release by plotting the in
vitro data of best formulation (LF5+ZF5) for zero order and first order, Higuchi and
Korsmayer pappas equation were observed the slope value and regression co-
efficient are given in table No. 9.19 and 9.21. The result of table showed that the
formulation (LF5+ZF5) follow zero order and release the drug through polymeric
membrane by following anomalous transport (Non-Fickian) diffusion.
From the study it can be concluded that the polymer viscosity, concentration
as well as the nature of polymer play an important role in developing the controlled
release dosage form.
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11. CONCLUSION
The study was undertaken with the aim to formulate the Lamivudine and
Zidovudine controlled release bilayer matrix tablets by using different grades of
polymer like HPMC (K100 and K 15) at different concentrations.
The polymer HPMC K 15 used in the formulation (LF5+ZF5) at 25%w/w of
the drug showed the better controlled drug release ( Lamivudine= 97.79% w/v and
Zidovudine=98.68% w/v)  upto 12 hrs. This was selected as the best formulation.
This formulation was reduce the frequent dosing, release the drug at
controlled manner, increase efficacy, reduces the side effect and improved the
patient’s compliance. This combination reduces the risk of emergence of resistance
to anti-retroviral drugs.
As it fulfills all the requirements of controlled release tablets and this study
encourages further clinical trials and long term stability study for best formulation.
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